Document:

Tax Matters Agreement dated as of July 1, 2008

 Exhibit 10.36.2 
 EXECUTION COPY 
 TAX MATTERS AGREEMENT 
 by and among 
 APPLERA CORPORATION 
 AND ITS AFFILIATES, 
 and 

CELERA CORPORATION 
 AND ITS
AFFILIATES, 
  
 Dated 
 July 1, 2008 

 TAX MATTERS AGREEMENT 
 THIS TAX MATTERS AGREEMENT (this “Agreement”) dated as of July 1, 2008, by and among Applera Corporation, a Delaware corporation
(“Applera”), each Applera Affiliate, Celera Corporation, a Delaware corporation (“Celera”), and each Celera Affiliate (the “Parties”) is entered into in connection with the Split-Off. Capitalized terms used in this
Agreement are defined herein. 
 W I T N E S S E T H: 
 WHEREAS, as of the date hereof, Applera and its direct and indirect domestic subsidiaries are members of an Affiliated Group, of which Applera is the
common parent; 
 WHEREAS, Applera, acting through its direct and indirect subsidiaries, currently conducts a number of businesses, including
(i) the Applera Business, and (ii) the Celera Business; 
 WHEREAS, the Board of Directors of Applera has determined that it is
appropriate, desirable and in the best interests of Applera and its stockholders to separate Applera into two separate, independent and publicly traded companies, (i) one comprising the Celera Business, which shall be owned and conducted,
directly or indirectly, by Celera, and (ii) one comprising the Applera Business which shall continue to be owned and conducted, directly or indirectly, by Applera; 
 WHEREAS, in order to effect such separation, (i) Applera will contribute to the capital of Celera the assets of the Celera Business, including the stock of Berkeley Heart Laboratories (“BHL”), Axys
Pharmaceuticals, Inc., PE AgGen, Inc., GenScope, Inc. and Paracel, Inc.; and have Celera assume liabilities of the Celera Business (together, the “Contribution”) and (ii) all of the stock of Celera will be exchanged on a one-for-one
basis for all of the outstanding Applera – CRA Tracking Stock (the “Exchange” and together with the “Contribution,” the “Split-Off”). 
 WHEREAS, Applera and Celera have determined that it is necessary and desirable, as part of the Split-Off, to allocate, transfer, retain or assign to the Celera Group, the Celera Group Assets and Celera Group
Liabilities, and to allocate, transfer, retain or assign to the Applera Group, the Applied Biosystems Group Assets and Applied Biosystems Group Liabilities; 
 WHEREAS, it is the intention of the Parties that the Split-Off qualify as a reorganization within the meaning of sections 368(a)(1)(D) and 355 of the Code and this Agreement is hereby adopted as a plan of
reorganization within the meaning of section 368 of the Code; and 
 WHEREAS, in contemplation of the Split-Off, pursuant to which the Celera
Group will cease to be members of the Affiliated Group of which Applera is the parent, the Parties have determined to enter into this Agreement, setting forth their agreement with respect to certain tax matters. 
  

 2 

 AGREEMENT 
 NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the Parties hereby agree as follows: 
  

	Section 1.	Definitions. 

 “Affiliated Group”
means an affiliated group of corporations within the meaning of section 1504(a)(1) of the Code that files a consolidated return for United States federal Income Tax purposes. 
 “After Tax Amount” means any additional amount necessary to reflect the hypothetical Tax consequences of the receipt or accrual of any
payment required to be made under this Agreement (including payment of an additional amount or amounts hereunder and the effect of the deductions available for interest paid or accrued and for Taxes such as state and local Income Taxes), determined
by using the highest applicable statutory corporate Income Tax rate (or rates, in the case of an item that affects more than one Tax) for the relevant taxable period (or portion thereof). 
 “Agreement” shall have the meaning set forth in the preamble hereto. 
 “Applera” shall have the meaning set forth in the preamble hereto. 
 “Applera Affiliate” means any corporation or other entity directly or indirectly “controlled” by Applera where
“control” means the ownership of fifty percent (50%) of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of such corporation or other entity, but at all times excluding Celera and all Celera Affiliates. 
 “Applera
Business” means all of the businesses and operations conducted by Applera and the Applera Affiliates, excluding the Celera Business at any time, whether prior to, or after the Split-Off Date. 
 “Applera Group” means the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of other
jurisdictions, of which Applera is the common parent corporation, and any corporation or other entity which may be, may have been or may become a member of such group from time to time, but excluding any member of the Celera Group. 
 “Applera-CRA Tracking Stock” means the Applera Corporation-Celera Group common stock. 
 “Applera Sharing Percentage” means as of the close of business on the first trading day after the Split-Off Date, the percentage of
Applera’s market capitalization as compared to the combined market capitalization of Applera and Celera. 
  

 3 

 “Applied Biosystems Group Assets” shall mean the assets of Applera after the Split-Off
Date, as determined under the Separation Agreement by and among the Parties. 
 “Applied Biosystems Group Liabilities” shall
mean the liabilities of Applera after the Split-Off Date, as determined under the Separation Agreement by and among the Parties. 
 “Audit” means any audit, assessment of Taxes, other examination by any Taxing Authority, proceeding, or appeal of such a proceeding relating to Taxes, whether administrative or judicial, including proceedings relating to
competent authority determinations. 
 “BHL” shall have the meaning set forth in the preamble hereto. 
 “BHL Affiliates” means any corporation or other entity directly or indirectly “controlled” by BHL at the time in question,
where “control” means the ownership of fifty percent (50%) of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or indirectly, of the power to direct or cause the direction of
the management or policies of such corporation or other entity. 
 “Big Dye Agreement” means the supply agreement among
Applera and Celera for Big Dye Terminators. 
 “Carryback Period” shall have the meaning set forth in Section 3.05.

 “Celera” shall have the meaning set forth in the preamble hereto. 
 “Celera Affiliate” means any corporation or other entity directly or indirectly “controlled” by Celera at the time in
question, where “control” means the ownership of fifty percent (50%) of the ownership interests of such corporation or other entity (by vote or value) or the possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of such corporation or other entity. 
 “Celera Group Assets” shall mean the assets
of Celera after the Split-Off Date, as determined under the Separation Agreement by and among the Parties. 
 “Celera
Business” means the business and operations conducted by Celera and the Celera Affiliates as such business and operations will continue after the Split-Off Date. 
 “Celera Business Records” shall have the meaning set forth in Section 9.02(b). 
 “Celera Group” means the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of other jurisdictions, of which Celera will be the common parent corporation immediately after
the Split-Off and including any corporation or other entity which may become a member of such group from time to time. 
 “Celera
Group Liabilities” shall mean the liabilities of Celera after the Split-Off Date, as determined under the Separation Agreement by and among the Parties. 
  

 4 

 “Celera Separate Tax Amount” shall mean with respect to any Tax Return, the amount of
Taxes attributable to a Post-Split-Off Period that Celera and each Celera Affiliate would have incurred if they had filed a consolidated return, combined return or a separate return, as the case may be, separate from the members of the Applera
Group, for the relevant Tax period, and such amount shall be computed by Applera in a manner consistent with (i) general Tax accounting principles, (ii) the Code and the Treasury regulations promulgated thereunder, and (iii) past
practice. 
 “Celera Sharing Percentage” means as of the close of business on the first trading day after the Split-Off
Date, the percentage of Celera’s market capitalization as compared to the combined market capitalization of Applera and Celera. 
 “Code” means the Internal Revenue Code of 1986, as amended. 
 “Combined Return” means any Tax
Return, other than with respect to United States federal Income Taxes, filed on a consolidated, combined (including nexus combination, worldwide combination, domestic combination, line of business combination or any other form of combination) or
unitary basis wherein Celera or one or more Celera Affiliates join in the filing of such Tax Return (for any taxable period or portion thereof) with Applera or one or more Applera Affiliates. 
 “Consolidated Return” means any Tax Return with respect to United States federal Income Taxes filed on a consolidated basis wherein
Celera or one or more Celera Affiliates join in the filing of such Tax Return (for any taxable period or portion thereof) with Applera or one or more Applera Affiliates. 
 “Contribution” shall have the meaning set forth in the recitals hereto. 
 “Contribution Taxes” shall mean any U.S. federal income tax imposed relating to the Contribution, including as a result of the Parties entering into the IP Access Agreements; provided, however, that
Contribution Taxes shall not include Taxes related to the Big Dye Agreement. For the avoidance of doubt, Contribution Taxes shall not include any Exchange Taxes. 
 “Estimated Tax Installment Date” means, with respect to United States federal Income Taxes, the estimated Tax installment due dates prescribed in section 6655(c) of the Code and, in the case of any
other Tax, means any other date on which an installment payment of an estimated amount of such Tax is required to be made. 
 “Exchange” shall have the meaning set forth in the recitals hereto. 
 “Exchange Taxes” means any
Taxes imposed on, or increase in Taxes incurred by, Applera or any Applera Affiliate (without regard to whether such Taxes are offset or reduced by any Tax Asset, Tax Item, or otherwise) resulting from, or arising in connection with, the failure of
the Exchange to qualify as a transaction in which no income, gain or loss is recognized 

  

 5 

 
pursuant to sections 355 and 368(a)(1)(D) of the Code (including any Tax resulting from the application of section 355(d) or section 355(e) of the Code to
the Exchange) or corresponding provisions of the laws of any other jurisdictions. Any Income Tax referred to in the immediately preceding sentence shall be determined using the highest applicable statutory corporate Income Tax rate for the relevant
taxable period (or portion thereof). 
 “Filing Party” shall have the meaning set forth in Section 8.01. 
 “Final Determination” means the final resolution of liability for any Tax for any taxable period, by or as a result of (i) a final
and unappealable decision, judgment, decree or other order by any court of competent jurisdiction; (ii) a final settlement with the IRS, a closing agreement or accepted offer in compromise under section 7121 or section 7122 of the Code, or a
comparable agreement under the laws of other jurisdictions, which resolves the entire Tax liability for any taxable period; (iii) any allowance of a refund or credit in respect of an overpayment of Tax, but only after the expiration of all
periods during which such refund may be recovered by the jurisdiction imposing the Tax; or (iv) any other final disposition, including by reason of the expiration of the applicable statute of limitations. 
 “Income Tax” means any federal, state, local or foreign Tax determined (in whole or in part) by reference to net income, net worth,
gross receipts or capital, or any such Taxes imposed in lieu of such a Tax. For the avoidance of doubt, the term “Income Tax” includes any franchise Tax, net worth, gross receipts, capital or any such Taxes imposed in lieu of such a Tax.

 “Income Tax Return” means any Tax Return relating to any Income Tax. 
 “IP Access Agreements” means the agreements entered into by the Parties to license IP and supply goods to the other Party for a period
of time after the Split-Off. 
 “IRS” means the United States Internal Revenue Service or any successor thereto, including
its agents, representatives, and attorneys. 
 “Joint Responsibility Item” means any Tax Item for which the non-Filing
Party’s responsibility under this Agreement could exceed one hundred thousand dollars ($100,000), but not a Sole Responsibility Item. 
 “Non-Income Tax Return” means any Tax Return relating to any Tax other than an Income Tax. 
 “Officer’s Certificate” means a letter executed by an officer of Applera or Celera and provided to Tax Counsel as a condition for the completion of a Tax Opinion or Supplemental Tax Opinion. 
 “Owed Party” shall have the meaning set forth in Section 7.05. 
 “Owing Party” shall have the meaning set forth in Section 7.05. 
  

 6 

 “Parties” shall have the meaning set forth in the preamble hereto. 
 “Payment Period” shall have the meaning set forth in Section 7.05(e). 
 “Post-Split-Off Period” means any taxable period (or portion thereof) beginning after the Split-Off Date. 
 “Pre-Split-Off Period” means any taxable period (or portion thereof) ending on or before the Split-Off Date. 
 “Proposed Merger” means the proposed merger of Applera with and into Invitrogen Corporation or an entity wholly owned by Invitrogen
Corporation. 
 “Ruling” means any private letter ruling issued by the IRS in connection with the Split-Off in
response to a request for such a private letter ruling filed by Applera (or any Applera Affiliate). 
 “Ruling Documents”
means (i) the request for a Ruling filed with the IRS, together with any supplemental filings or other materials subsequently submitted on behalf of Applera, the Applera Affiliates and Applera’s shareholders to the IRS, the appendices
and exhibits thereto, and any Ruling issued by the IRS to Applera (or any Applera Affiliate) in connection with the Split-Off and (ii) any similar filings submitted to, or rulings issued by, any other Taxing Authority in connection with the
Split-Off. 
 “Separation Agreement” means the separation agreement by and between Applera and Celera. 
 “Sole Responsibility Item” means any Tax Item for which the non-Filing Party has the entire economic liability under this Agreement.

 “Split-Off” shall have the meaning set forth in the recitals hereto. 
 “Split-Off Date” means the close of business on the date which the Split-Off is effected. 
 “Straddle Period” shall mean any taxable period that begins on or before and ends after the Split-Off Date. 
 “Supplemental Tax Opinion” shall have the meaning set forth in Section 4.02(d). 
 “Tax Asset” means any Tax Item that has accrued for Tax purposes, but has not been realized during the taxable period in which it has
accrued, and that could reduce a Tax in another taxable period, including a net operating loss, net capital loss, research and development tax credit, investment tax credit, foreign tax credit, charitable deduction or credit related to alternative
minimum tax or any other Tax credit. 
  

 7 

 “Tax Benefit” means a reduction in the Tax liability (or increase in refund or credit or
any item of deduction or expense) of a taxpayer (or of the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for any taxable period. Except as
otherwise provided in this Agreement, a Tax Benefit shall be deemed to have been realized or received from a Tax Item in a taxable period only if and to the extent that the Tax liability of the taxpayer (or of the Affiliated Group, or similar group
of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for such period, after taking into account the effect of the Tax Item on the Tax liability of such taxpayer (or of the Affiliated
Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) in the current period and all prior periods, is less than it would have been had such Tax liability been
determined without regard to such Tax Item. 
 “Tax Counsel” means a nationally recognized law firm selected by Applera to
provide a Tax Opinion. 
 “Tax Detriment” means an increase in the Tax liability (or reduction in refund or credit or any
item of deduction or expense) of a taxpayer (or of the Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for any taxable period. Except as
otherwise provided in this Agreement, a Tax Detriment shall be deemed to have been realized or incurred from a Tax Item in a taxable period only if and to the extent that the Tax liability of the taxpayer (or of the Affiliated Group, or similar
group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) for such period, after taking into account the effect of the Tax Item on the Tax liability of such taxpayer (or of the
Affiliated Group, or similar group of entities as defined under corresponding provisions of the laws of any other jurisdiction, of which it is a member) in the current period and all prior periods, is more than it would have been had such Tax
liability been determined without regard to such Tax Item. 
 “Tax Item” means any item of income, gain, loss, deduction,
expense or credit, or other attribute that may have the effect of increasing or decreasing any Tax. 
 “Tax Opinion” means
an opinion issued by Tax Counsel as one of the conditions to completing the Split-Off addressing certain United States federal Income Tax consequences of the Split-Off under section 355 of the Code.  
 “Tax Return” means any return, report, certificate, form or similar statement or document (including any related or supporting
information or schedule attached thereto and any information return, amended tax return, claim for refund or declaration of estimated Tax) required to be supplied to, or filed with, a Taxing Authority in connection with the determination, assessment
or collection of any Tax or the administration of any laws, regulations or administrative requirements relating to any Tax. 
 “Taxes” means all federal, state, local or foreign taxes, charges, fees, duties, levies, imposts, rates or other assessments, including income, gross receipts, excise, property, sales, use, license, capital stock, transfer,
franchise, payroll, withholding, social security, value added or 

  

 8 

 
other taxes, (including any interest, penalties or additions attributable thereto) and a “Tax” shall mean any one of such Taxes. 
 “Taxing Authority” means any governmental authority or any subdivision, agency, commission or authority thereof or any
quasi-governmental or private body having jurisdiction over the assessment, determination, collection or imposition of any Tax (including the IRS). 
  

	Section 2.	Preparation and Filing of Tax Returns. 

 2.01.
Applera’s Responsibility. Subject to the other applicable provisions of this Agreement, Applera shall have sole and exclusive responsibility for the preparation and filing of: 
 (a) all Consolidated Returns and all Combined Returns for any taxable period; 
 (b) all Income Tax Returns (other than Consolidated Returns and Combined Returns) with respect to Applera and/or any Applera Affiliate for any taxable
period; 
 (c) all Non-Income Tax Returns with respect to Applera, any Applera Affiliate, or the Applera Business or any part thereof for any
taxable period; and 
 (d) all Non-Income Tax Returns with respect to Celera, any Celera Affiliate, or the Celera Business or any part
thereof, that are required to be filed (taking into account any extension of time which has been requested or received) on or prior to the Split-Off Date. 
 2.02. Celera’s Responsibility. Celera shall have sole and exclusive responsibility for the preparation and filing of: 
 (a) all Income Tax Returns (other than Consolidated Returns and Combined Returns) with respect to Celera and/or any Celera Affiliate for any taxable period that are required to be filed after the Split-Off Date; and

 (b) all Non-Income Tax Returns with respect to Celera, any Celera Affiliate, or the Celera Business or any part thereof, that are required
to be filed (taking into account any extension of time which has been requested or received) after the Split-Off Date. 
 2.03. Agent.
Subject to the other applicable provisions of this Agreement, Celera hereby irrevocably designates, and agrees to cause each Celera Affiliate to so designate, Applera as its sole and exclusive agent and attorney-in-fact to take such action
(including execution of documents) as Applera, in its sole discretion, may deem appropriate in any and all matters (including Audits) relating to any Tax Return described in Section 2.01, subject, however, to the joint control provisions and
control by a non-Filing Party provisions in Section 8. 
 2.04. Manner of Tax Return Preparation. 
 (a) Unless otherwise required by a Taxing Authority, the Parties hereby agree to prepare and file all Tax Returns, and to take all other actions, in a
manner consistent with (1) this 

  

 9 

 
Agreement, (2) any Tax Opinion, (3) any Supplemental Tax Opinion, and (4) any Ruling. All Tax Returns shall be filed on a timely basis (taking
into account applicable extensions) by the Party responsible for filing such returns under this Agreement. 
 (b) Subject to the other
applicable provisions of this Agreement, Applera shall have the exclusive right, in its sole discretion, with respect to any Tax Return described in Section 2.01, to determine (1) the manner in which such Tax Return shall be prepared and
filed, including the elections, method of accounting, positions, conventions and principles of taxation to be used and the manner in which any Tax Item shall be reported, (2) whether any extensions shall be requested, (3) the elections
that will be made by Applera, any Applera Affiliate, Celera, and/or any Celera Affiliate on such Tax Return, (4) whether any amended Tax Returns shall be filed, (5) whether any claims for refund shall be made, (6) whether any refunds
shall be paid by way of refund or credited against any liability for the related Tax, and (7) whether to retain outside firms to prepare and/or review such Tax Returns. 
  

	Section 3.	Liability for Ordinary Course Taxes. 

 3.01.
Applera’s Liability for Ordinary Course Taxes. Except as provided in Sections 4.01 and 4.03, Applera shall be liable for the following Taxes, and shall be entitled to receive and retain all refunds of: 
 (a) all Taxes attributable to the Applera Group or the Applera Business, in each case for any and all periods, 
 (b) except for Taxes related to BHL and BHL Affiliates, all Taxes attributable to the Celera Group, the Celera Group Assets or the Celera Business, in
each case for any and all Pre-Split-Off Periods, 
 (c) except for Taxes related to BHL and BHL Affiliates, all Taxes for which the Celera
Group may be liable by virtue of any agreement or arrangement with respect to Taxes (other than pursuant to this Agreement or any other agreements entered into in connection with the Split-Off) entered into on or prior to the Split-Off Date.

 3.02. Celera’s Liability for Ordinary Course Taxes. Except as provided in Sections 4.01 and 4.03, Celera and each Celera
Affiliate shall be jointly and severally liable for (i) all Taxes attributable to any and all members of the Celera Group or the Celera Group Assets or the Celera Business, in each case for any and all Post-Split-Off Periods and (ii) all
Taxes related to BHL and the BHL Affiliates for any and all periods. 
 3.03. Straddle Periods. For purposes of Sections 3.01 and
3.02, in the case of any Straddle Period, (i) property taxes and exemptions, allowances or deductions that are calculated on an annualized basis shall be apportioned between the Pre-Split-Off Period and the Post-Split-Off Period on a daily
pro-rata basis and (ii) all other Taxes shall be apportioned between the Pre-Split-Off Period and the Post-Split-Off Period on a closing of the books basis as of the close of business on the Split-Off Date. 
  

 10 

 3.04. Refunds. The amount or economic benefit of any refunds, credits or offsets of Taxes relating
to (i) Celera, the Celera Group Assets or the Celera Business for a Pre-Split-Off Period shall be for the account of Applera, (ii) Celera, the Celera Group Assets or the Celera Business for a Post-Split-Off Period shall be for the account
of Celera, and (iii) the Applera Group, the Applied Biosystems Group Assets or the Applera Business shall for the account of Applera. 
 3.05. Carryback. Notwithstanding Section 3.04, to the extent permitted by law, the Celera Group shall elect to forego a carryback of any net operating losses, capital losses, credits or other Tax benefits to a taxable period, or
portion thereof, ending on or before the Split-Off Date unless Applera otherwise elects, in its sole discretion, to allow such carryback. To the extent that Celera is required under law to carry back Tax Assets described in this section, Applera
agrees to pay to Celera the United States federal Income Tax Benefit from the use in any Pre-Split-Off Period (the “Carryback Period”) of a carryback of any such Tax Asset of the Celera Group from a Post-Split-Off Period (other than a
carryback of any Tax Asset attributable to Exchange Taxes for which the liability is borne by Applera or any Applera Affiliate). If subsequent to the payment by Applera to Celera of the United States federal Income Tax Benefit of a carryback of a
Tax Asset of the Celera Group, there shall be a Final Determination which results in a (1) change to the amount of the Tax Asset so carried back or (2) change to the amount of such United States federal Income Tax Benefit, Celera shall
repay to Applera, or Applera shall repay to Celera, as the case may be, any amount which would not have been payable to such other Party pursuant to this Section 3.05 had the amount of the benefit been determined in light of these events.
Nothing in this Section 3.05 shall require Applera to file an amended Tax Return or claim for refund of United States federal Income Taxes; provided, however, that Applera shall use its commercially reasonable efforts to use any
carryback of a Tax Asset of the Celera Group that is carried back under this Section 3.05. 
 3.06. Celera Tax Assets on Applera
Post-Split-Off Period Returns. With respect to any Post-Split-Off Period, to the extent that any Tax Assets relating to the Celera Business attributable to Pre-Split-Off Periods remain with the Applera Group after the Split-Off: (i) to the
extent that the Celera Group generates sufficient income or recognizes sufficient gains in a given Tax period that the Celera Group would have been able to utilize such Tax Assets (that were not already utilized by Applera pursuant to clause (ii))
on a pro-forma basis, Applera shall compensate Celera for such utilizable amount on a pro-forma basis, and (ii) to the extent that (A) Celera Group does not generate sufficient income or recognize sufficient gains in such Tax period and
(B) Applera utilizes such Tax Assets on its Tax Returns for such Tax Period, then Applera shall not be required to compensate Celera for Applera’s utilization of such Tax Assets. For the avoidance of doubt, this section is intended to
provide that Celera is compensated for a Celera-related Tax Asset that remains with the Applera Group after the Split-Off Date only if and to the extent that Celera would have been able to utilize such Tax Asset on or before the time that the
Applera Group actually utilizes such Tax Asset. For the avoidance of doubt, this section shall apply to any gain related to Exchange Taxes in the same manner as it applies to any other income or gains. 
 3.07. Payment of Tax Liability. If one Party is liable or responsible for Taxes, under Sections 3.01 through 3.06, with respect to Tax Returns for
which another party is responsible 

  

 11 

 
for preparing and/or filing, or with respect to Taxes that are paid by another Party, then the liable or responsible Party shall pay the Taxes (or a
reimbursement of such Taxes) to the other Party pursuant to Section 7.05. 
 3.08. Computation. With respect to any Tax Return
filed by Applera for which Celera is liable for Taxes under this Section 3, Applera shall provide Celera with a written calculation in reasonable detail (including copies of work sheets and other materials used in preparation thereof) setting
forth the amount of any Celera Separate Tax Amount or estimated Celera Separate Tax Amount (for purposes of Section 7.01). Celera shall have the right to review and comment on such calculation. Any dispute with respect to such calculation shall
be resolved pursuant to Section 9.03; provided, however, that, notwithstanding any dispute with respect to any such calculation, in no event shall any payment attributable to the amount of any Celera Separate Tax Amount or
estimated Celera Separate Tax Amount be paid later than the date provided in Section 7. 
  

	Section 4.	Exchange Taxes, Contribution Taxes and Deconsolidation. 

 4.01. Exchange Taxes. 
 (a) Applera’s Liability for Exchange Taxes. Notwithstanding Sections 3.01 through 3.03,
Applera and each Applera Affiliate shall be jointly and severally liable for any Exchange Taxes attributable to, caused by, or resulting from, one or more of the following: 
 (i) any action or omission by Applera (or any Applera Affiliate) inconsistent with any material, information, covenant or representation related to
Applera, any Applera Affiliate, or the Applera Business in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling (for the avoidance of doubt, disclosure of any action or fact that is inconsistent with any
material, information, covenant or representation submitted to Tax Counsel, the IRS, or other Taxing Authority, as applicable, in connection with an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling shall
not relieve Applera (or any Applera Affiliate) of liability under this Agreement); 
 (ii) any action or omission by Applera (or any Applera
Affiliate), after the Split-Off (including any act or omission that is in furtherance of, connected to, or part of a plan or series of related transactions (within the meaning of section 355(e) of the Code) occurring on or prior to the Split-Off),
including a cessation, transfer to affiliates, or disposition of its active trades or businesses, stock buyback or payment of an extraordinary dividend; 
 (iii) any acquisition of any stock or assets of Applera (or any Applera Affiliate) by one or more other persons (other than Celera or a Celera Affiliate) prior to or following the Split-Off; or 
 (iv) any issuance of stock by Applera (or any Applera Affiliate), including any issuance pursuant to the exercise of employee stock options or other
employment related arrangements or the exercise of warrants, or change in ownership of stock in Celera (or any Celera Affiliate). 
  

 12 

 (b) Celera’s Liability for Exchange Taxes. Notwithstanding Sections 3.01 through 3.03, Celera
and each Celera Affiliate shall be jointly and severally liable for any Exchange Taxes attributable to, caused by, or result from, one or more of the following: 
 (i) any action or omission by Celera (or any Celera Affiliate) after the Split-Off at any time, that is inconsistent with any material, information, covenant or representation related to Celera, any Celera Affiliate,
or the Celera Business in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling (for the avoidance of doubt, disclosure by Celera (or any Celera Affiliate) to Applera (or any Applera Affiliate) of any
action or fact that is inconsistent with any material, information, covenant or representation submitted to Tax Counsel, the IRS, or other Taxing Authority, as applicable, in connection with an Officer’s Certificate, Tax Opinion, Supplemental
Tax Opinion, Ruling Documents or Ruling shall not relieve Celera (or any Celera Affiliate) of liability under this Agreement); 
 (ii) any
action or omission by Celera (or any Celera Affiliate), after the Split-Off Date (including any act or omission that is in furtherance of, connected to, or part of a plan or series of related transactions (within the meaning of section 355(e) of the
Code) occurring on or prior to the Split-Off Date) including a cessation, transfer to affiliates or disposition of the active trades or businesses, stock buyback or payment of an extraordinary dividend; 
 (iii) any acquisition of any stock or assets of Celera (or any Celera Affiliate) by one or more other persons (other than Applera or any Applera
Affiliate) following the Split-Off; or 
 (iv) any issuance of stock by Celera (or any Celera Affiliate) after the Split-Off, including any
issuance pursuant to the exercise of employee stock options or other employment related arrangements or the exercise of warrants, or change in ownership of stock in Celera (or any Celera Affiliate) after the Split-Off. 
 (c) Joint Liability for Remaining Exchange Taxes. Applera and each Applera Affiliate shall be liable for the Applera Sharing Percentage and Celera
and each Celera Affiliate shall be jointly and severally liable for the Celera Sharing Percentage of any Exchange Taxes (including costs related or attributable to such Exchange Taxes) not otherwise allocated by Sections 4.01(a) or (b) (e.g.,
because of a retroactive change in law). 
 (d) Representation. Each of Applera and Celera represents that, as of the date of this
Agreement, neither it nor its Affiliates know of any fact (other than the Proposed Merger) that may cause the Exchange to fail to qualify under section 355 or section 368(a)(1)(D) of the Code. 
 4.02. Continuing Covenants. 
  

 13 

 (a) In General. Each of Applera (for itself and each Applera Affiliate) and Celera (for itself and
each Celera Affiliate) agrees (1) not to take any action reasonably expected to result in an increased Tax liability to the other, a reduction in a Tax Asset of the other or an increased liability to the other under this Agreement, and
(2) to take any action reasonably requested by the other that would reasonably be expected to result in a Tax Benefit or avoid a Tax Detriment to the other, provided, in either such case, that the taking or refraining to take such action does
not result in any additional cost not fully compensated for by the other Party or any other adverse effect to such Party. The Parties hereby acknowledge that the preceding sentence is not intended to limit, and therefore shall not apply to, the
rights of the Parties with respect to matters otherwise covered by this Agreement. 
 (b) Celera Restrictions. Celera agrees that it
will not knowingly take or fail to take, or permit any Celera Affiliate to knowingly take or fail to take, any action where such action or failure to act would be inconsistent with any material, information, covenant or representation that relates
to facts or matters related to Celera (or any Celera Affiliate) or within the control of Celera and is contained in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling (except where such material,
information, covenant or representation was not previously disclosed to Celera) other than as permitted by this Section 4.02. For this purpose an action is considered inconsistent with a representation if the representation states that there is
no plan or intention to take such action. Celera agrees that it will not take (and it will cause the Celera Affiliates to refrain from taking) any position on a Tax Return that is inconsistent with the treatment of the Exchange as transactions in
which no income, gain, or loss is recognized pursuant to section 355 of the Code. 
 (c) Applera Restrictions. Applera agrees that it
will not knowingly take or fail to take, or permit any Applera Affiliate to knowingly take or fail to take, any action where such action or failure to act would be inconsistent with any material, information, covenant or representation that relates
to facts or matters related to Applera (or any Applera Affiliate) or within the control of Applera and is contained in an Officer’s Certificate, Tax Opinion, Supplemental Tax Opinion, Ruling Documents or Ruling other than as permitted by this
Section 4.02. For this purpose an action is considered inconsistent with a representation if the representation states that there is no plan or intention to take such action. Applera agrees that it will not take (and it will cause the Applera
Affiliates to refrain from taking) any position on a Tax Return that is inconsistent with the treatment of the Exchange as transactions in which no income, gain, or loss is recognized pursuant to section 355 of the Code. 
 (d) Certain Celera Actions Following the Split-Off. Celera agrees that, during the two (2) year period following the Split-Off, without first
obtaining, at Celera’s own expense, either a supplemental opinion from Tax Counsel that such action will not result in Exchange Taxes (a “Supplemental Tax Opinion”) or a Ruling that such action will not result in Exchange Taxes,
unless in any such case Applera and Celera agree otherwise in writing, Celera shall not (1) sell all or substantially all of the assets of Celera or any Celera Affiliate, (2) merge Celera, or any Celera Affiliate with another entity,
without regard to which party is the surviving entity, (3) transfer any assets of Celera in a transaction described in section 351 (other than a transfer to a corporation which files a consolidated return with Celera and which is wholly-owned,
directly or indirectly, by Celera) or subparagraph (C) or (D) of section 368(a)(1) of the Code, (4) issue stock 

  

 14 

 
of Celera or any Celera Affiliate (or any instrument that is convertible or exchangeable into any such stock) in an acquisition or public or private offering
(excluding any issuance pursuant to the exercise of employee stock options or other employment related arrangements having customary terms and conditions and that satisfy the requirements of Treasury Regulations section 1.355-7(d)(8), or any
successor provision thereto), or (5) facilitate or otherwise participate in any acquisition of stock in Celera that would result in any shareholder owning five percent (5%) or more of the outstanding stock of Celera. Celera (or any Celera
Affiliate) shall only undertake any of such actions after Applera’s receipt of such Supplemental Tax Opinion or Ruling and pursuant to the terms and conditions of any such Supplemental Tax Opinion or Ruling or as otherwise consented to in
writing in advance by Applera; provided, however, that if Celera contemplates entering into a transaction described in this section and Celera acknowledges in writing that it would have sole liability for any Exchange Taxes under
Section 4.01(b) that might arise from such transaction and can demonstrate to the reasonable satisfaction of Applera that Celera can satisfy its liability for any such Exchange Taxes, Applera shall consent to Celera’s entering into such
transaction without further restriction; and provided, further, that in the event that (i) Applera completes a transaction that results in a tax being imposed on Applera under Section 355(e) of the Code (including without
limitation the Proposed Merger), after such completion, Celera shall no longer be subject to the restrictions under clause 4 and clause 5, or (ii) the Split-off is determined to be taxable, then these restrictions shall no longer apply. The
Parties hereby agree that they will act in good faith to take all reasonable steps necessary to amend this Section 4.02(d), from time to time, by mutual agreement, to (i) add certain actions to the list contained herein, or
(ii) remove certain actions from the list contained herein, in either case, in order to reflect any relevant change in law, regulation or administrative interpretation occurring after the date of this Agreement. 
 (e) Notice of Specified Transactions. Not later than three (3) days after the public announcement regarding any of the transactions described
in Section 4.02(d) (including a public announcement regarding Celera’s intent to enter into any such transaction) Celera shall provide written notice of such transaction to Applera. 
 4.03. Other Taxes. 
 (a)
Contribution Taxes. Notwithstanding Sections 3.01 through 3.03, but subject to Section 4.03(c), if any Contribution Taxes are imposed on Applera or Celera, Applera and Celera shall each be responsible for 50 percent of such Contribution
Taxes. For the avoidance of doubt, this equal sharing of Contribution Taxes shall not be affected by the availability of any corresponding deductions resulting from such Contribution Taxes. 
 (b) Big Dye Agreement Taxes. Notwithstanding Sections 3.01 through 3.03, but subject to Section 4.03(c), the Parties intend to report the Big
Dye Agreement as giving rise to current taxable income to Applera, and corresponding current and future deductions to Celera. Celera shall pay to Applera (i) the present value of the Tax benefit expected to be realized by Celera with respect to
such current and future deductions plus (ii) 50 percent of the difference between (A) the Tax imposed on Applera resulting from the Big Dye Agreement and (B) the present value of the Tax benefit expected to be realized by Celera (as
determined in 4.03(b)(i)). 
  

 15 

 (c) Treatment if Proposed Merger is Completed. To the extent allowable under applicable law, if
the Proposed Merger is completed and results in the Split-off being taxable, Applera and Celera shall report the entering into the IP Access Agreements as taxable transactions for U.S. federal income tax purposes and the indemnification provisions
in Section 4.03(a) and (b) shall not apply. In such an event, Applera shall be responsible for the resulting tax imposed on Applera, and Celera shall pay Applera 50 percent of the present value of the Tax benefit expected to be realized by
Celera with respect to current and future deductions resulting from the Big Dye Agreement and the IP Access Agreement. 
 4.04. Allocation
of Tax Items. All Tax computations for (1) any Pre-Split-Off Periods ending on the Split-Off Date and (2) the immediately following taxable period of Celera or any Celera Affiliate, shall be made pursuant to the principles of section
1.1502-76(b) of the Treasury Regulations or of a corresponding provision under the laws of other jurisdictions, as reasonably determined by Applera, taking into account all reasonable suggestions made by Celera with respect thereto. 
 4.05. Allocation of Tax Assets. 
 (a)
In General. In connection with the Split-Off, Applera and Celera have set forth on Schedule 4.5 the Tax Assets allocated to Applera and Celera, and each of Applera and Celera agrees that each shall prepare all Tax Returns in a manner
consistent with such allocation, unless otherwise required by law. The Parties hereby agree that to the extent that Tax Assets are not shown in Schedule 4.5, such Tax Assets were incurred by Applera and shall remain with Applera. 
 (b) Earnings and Profits. Applera will advise Celera in writing of the decrease in Applera earnings and profits attributable to the Split-Off
under section 312(h) of the Code on or before the first anniversary of the Split-Off Date; provided, however, that Applera shall provide Celera with estimates of such amounts (determined in accordance with past practice) prior to such
anniversary as reasonably requested by Celera. 
  

	Section 5.	Employee Wages. 

 At Applera’s request, Celera
shall assume the Form W-2 and Form W-3 reporting obligations (including the filing of all forms necessary to comply with magnetic media reporting requirements) of Applera with respect to any employee of the Celera Business that Celera or any Celera
Affiliate employs during the calendar year which includes the Split-Off Date consistent with the procedures set forth in section 5 of Rev. Proc. 2004-53, 2004-34 I.R.B. 320. 
  

	Section 6.	Indemnification. 

 6.01. In General. Applera
and each member of the Applera Group shall jointly and severally indemnify Celera, each Celera Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any and all Taxes for which Applera or any
Applera Affiliate is liable under this Agreement and any loss, cost, damage or expense, including reasonable attorneys’ fees and costs, that is attributable to, or results from, the failure of Applera, 

  

 16 

 
any Applera Affiliate or any director, officer or employee to make any payment required to be made under this Agreement. Celera and each member of the Celera
Group shall jointly and severally indemnify Applera, each Applera Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any and all Taxes for which Celera or any Celera Affiliate is liable under
this Agreement and any loss, cost, damage or expense, including reasonable attorneys’ fees and costs, that is attributable to, or results from, the failure of Celera, any Celera Affiliate or any director, officer or employee to make any payment
required to be made under this Agreement. 
 6.02. Inaccurate or Incomplete Information. Applera and each member of the Applera Group
shall jointly and severally indemnify Celera, each Celera Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any cost, fine, penalty, or other expense of any kind attributable to the failure of
Applera or any Applera Affiliate in supplying Celera or any Celera Affiliate with inaccurate or incomplete information, in connection with the preparation of any Tax Return. Celera and each member of the Celera Group shall jointly and severally
indemnify Applera, each Applera Affiliate, and their respective directors, officers and employees, and hold them harmless from and against any cost, fine, penalty, or other expenses of any kind attributable to the failure of Celera or any Celera
Affiliate in supplying Applera or any Applera Affiliate with inaccurate or incomplete information, in connection with the preparation of any Tax Return. 
 6.03. No Indemnification for Tax Items. Nothing in this Agreement shall be construed as a guarantee of the existence or amount of any loss, credit, carryforward, basis or other Tax Item, whether past, present
or future, of Applera, any Applera Affiliate, Celera or any Celera Affiliate. In addition, for the avoidance of doubt, for purposes of determining any amount owed between the Parties hereto, all such determinations shall be made without regard to
any financial accounting tax asset or liability or other financial accounting items. 
  

	Section 7.	Payments. 

 7.01. Estimated Tax Payments.
Not later than ten (10) business days after each Estimated Tax Installment Date with respect to a taxable period for which a Consolidated Return or a Combined Return that includes a Celera Separate Tax Amount will be filed, Celera shall pay to
Applera on behalf of the Celera Group an amount equal to the amount of any estimated Celera Separate Tax Amount. 
 7.02. True-Up
Payments. Not later than ten (10) business days after filing a Tax Return, Celera shall pay to Applera, or Applera shall pay to Celera, as appropriate, an amount equal to the difference, if any, between the Celera Separate Tax Amount and
the aggregate amount paid by Celera with respect to such period under Section 7.01. 
 7.03. Redetermination Amounts. In the
event of a redetermination of any Tax Item reflected on any Consolidated Return or Combined Return (other than Tax Items relating to Exchange Taxes), as a result of a refund of Taxes paid, a Final Determination or any settlement or compromise with
any Taxing Authority which in any such case would affect the Celera Separate Tax Amount, Applera shall prepare a revised pro forma Tax Return in accordance with 

  

 17 

 
Section 2.04(b) for the relevant taxable period reflecting the redetermination of such Tax Item as a result of such refund, Final Determination,
settlement or compromise. Celera shall pay to Applera, or Applera shall pay to Celera, as appropriate, an amount equal to the difference, if any, between the Celera Separate Tax Amount reflected on such revised pro forma Tax Return and the Celera
Separate Tax Amount for such period as originally computed pursuant to this Agreement. 
 7.04. Payments of Refunds and Credits. If
one Party receives a refund or credit of any Tax to which the other Party is entitled pursuant to Section 3.04, the Party receiving such refund or credit shall pay to the other Party the amount of such refund or credit pursuant to
Section 7.05. 
 7.05. Payments Under This Agreement. In the event that one Party (the “Owing Party”) is required to
make a payment to another Party (the “Owed Party”) pursuant to this Agreement, then such payments shall be made according to this Section 7.05. 
 (a) In General. All payments shall be made to the Owed Party or to the appropriate Taxing Authority as specified by the Owed Party within the time prescribed for payment in this Agreement, or if no period is
prescribed, within ten (10) days after delivery of written notice of payment owing together with a computation of the amounts due. 
 (b) Treatment of Payments. Unless otherwise required by any Final Determination, the Parties agree that any payments made by one Party to another Party pursuant to this Agreement (other than (i) payments for the Celera Separate
Tax Amount for the Post-Split-Off Period, (ii) payments of After Tax Amounts pursuant to Section 7.05(d), and (iii) payments of interest pursuant to Section 7.05(e)) shall be treated for all Tax purposes as nontaxable payments
(dividend distributions or capital contributions, as the case may be) made immediately prior to the Split-Off and, accordingly, as not includible in the taxable income of the recipient or as deductible by the payor. 
 (c) Prompt Performance. All actions required to be taken (including payments) by any Party under this Agreement shall be performed within the time
prescribed for performance in this Agreement, or if no period is prescribed, such actions shall be performed promptly. 
 (d) After Tax
Amounts. If pursuant to a Final Determination it is determined that the receipt or accrual of any payment made under this Agreement (other than payments of interest pursuant to Section 7.05(e)) is subject to any Tax, the Party making such
payment shall be liable for (a) the After Tax Amount with respect to such payment and (b) interest at the rate described in Section 7.05(e) on the amount of such Tax from the date such Tax accrues through the date of payment of such
After Tax Amount. A Party making a demand for a payment pursuant to this Agreement and for a payment of an After Tax Amount with respect to such payment shall separately specify and compute such After Tax Amount. However, a Party may choose not to
specify an After Tax Amount in a demand for payment pursuant to this Agreement without thereby being deemed to have waived its right subsequently to demand an After Tax Amount with respect to such payment. 
  

 18 

 (e) Interest. Payments pursuant to this Agreement that are not made within the period prescribed
in this Agreement (the “Payment Period”) shall bear interest for the period from and including the date immediately following the last date of the Payment Period through and including the date of payment at a per annum rate equal to the
applicable rate under Section 6621 of the Code. Such interest will be payable at the same time as the payment to which it relates and shall be calculated on the basis of a year of three hundred sixty-five (365) days and the actual number
of days for which due. 
  

	Section 8.	Tax Proceedings. 

 8.01. In General. Except
as otherwise provided in this Agreement, the Party responsible for preparing and filing a Tax Return pursuant to Section 2 (the “Filing Party”) shall have the exclusive right, in its sole discretion, to control, contest, and represent
the interests of Applera, any Applera Affiliate, Celera, and/or any Celera Affiliate in any Audit relating to such Tax Return and to resolve, settle or agree to any deficiency, claim or adjustment proposed, asserted or assessed in connection with or
as a result of any such Audit; provided, however, that for purposes of this Section 8, Celera shall be treated as the Filing Party for all Tax Returns of BHL and BHL Affiliates (other than Consolidated Returns or Combined
Returns). The Filing Party’s rights shall extend to any matter pertaining to the management and control of an Audit, including execution of waivers, choice of forum, scheduling of conferences and the resolution of any Tax Item. Any costs
incurred in handling, settling, or contesting an Audit shall be borne by the Filing Party. 
 8.02. Participation of non-Filing Party.
Except as provided in Section 8.04, the non-Filing Party shall, at its own expense, have control over decisions to resolve, settle or otherwise agree to any deficiency, claim or adjustment with respect to any Sole Responsibility Item. Except as
provided in Section 8.04, the Filing Party, at its own expense, and the non-Filing Party, at its own expense, shall have joint control over decisions to resolve, settle or otherwise agree to any deficiency, claim or adjustment with respect to
any Joint Responsibility Item. Except as provided in Section 8.04, the Filing Party shall not settle any Audit it controls concerning a Tax Item on a basis that would reasonably be expected to adversely affect the non-Filing Party by at least
one hundred thousand dollars ($100,000) without obtaining such non-Filing Party’s consent, which consent shall not be unreasonably withheld, conditioned or delayed if failure to consent would adversely affect the Filing Party. 
 8.03. Notice. Within ten (10) days after a Party receives written notice of a proposed Audit adjustment that may give rise to an
indemnification obligation under this Agreement, such Party shall give notice to the other Party of such issue (such notice shall contain factual information, to the extent known, describing any asserted tax liability in reasonable detail), and
shall forward to the other Party copies of all notices and material communications with any Taxing Authority relating to such issue. Notwithstanding any provision in Section 9.15 to the contrary, if a Party to this Agreement fails to provide
the other Party notice as required by this Section 8.03, and the failure results in a detriment to the other Party then any amount which the other Party is otherwise required to pay pursuant to this Agreement shall be reduced by the amount of
such detriment. 
  

 19 

 8.04. Control of Exchange Tax and Contribution Tax Proceedings. Applera shall have the exclusive
right, in its sole discretion, to control, contest, and represent the interests of Applera, any Applera Affiliate, Celera, and/or any Celera Affiliate in any Audits relating to Exchange Taxes and Contribution Taxes and to resolve, settle or agree to
any deficiency, claim or adjustment proposed, asserted or assessed in connection with or as a result of any such Audit; provided, however, that Applera shall not settle any such audit with respect to Exchange Taxes or Contribution
Taxes with a Taxing Authority as part of a formal understanding with the Taxing Authority for a settlement on an issue or issues unrelated to such Exchange Taxes or Contribution Taxes that would reasonably be expected to result in a Tax liability to
Celera or any Celera Affiliate (including as a result of an indemnification obligation pursuant to this Agreement) in excess of one hundred thousand dollars ($100,000), without the prior consent of Celera, which consent shall not be unreasonably
withheld, conditioned or delayed. Applera’s rights shall extend to any matter pertaining to the management and control of such Audit, including execution of waivers, choice of forum, scheduling of conferences and the resolution of any Tax Item.
Celera may assume sole control of any Audits relating to Exchange Taxes if it acknowledges in writing that it has sole liability for any Exchange Taxes under Section 4.01(b) that might arise in such Audit and can demonstrate to the reasonable
satisfaction of Applera that it can satisfy its liability for any such Exchange Taxes. If Celera is unable to demonstrate to the reasonable satisfaction of Applera that it will be able to satisfy its liability for such Exchange Taxes, but
acknowledges in writing that it has sole liability for any Exchange Taxes under Section 4.01(b), Celera and Applera shall have joint control over the Audit. 
  

	Section 9.	Miscellaneous Provisions. 

 9.01.
Effectiveness. This Agreement shall become effective upon execution by the Parties hereto. 
 9.02. Cooperation and Exchange of
Information. 
 (a) Cooperation. Celera and Applera shall each cooperate fully (and each shall cause its respective affiliates to
cooperate fully) with all reasonable requests from another party for information and materials not otherwise available to the requesting party in connection with the preparation and filing of Tax Returns, claims for refund, and Audits concerning
issues or other matters covered by this Agreement or in connection with the determination of a liability for Taxes or a right to a refund of Taxes. Such cooperation shall include: 
 (i) the retention until the expiration of the applicable statute of limitations, and the provision upon request, of copies of all Tax Returns, books,
records (including information regarding ownership and Tax basis of property), documentation and other information relating to the Tax Returns, including accompanying schedules, related work papers, and documents relating to rulings or other
determinations by Taxing Authorities; 
 (ii) the execution of any document that may be necessary or reasonably helpful in connection with
any Tax Proceeding, or the filing of a Tax Return or refund claim by a member of the Applera Group or the Celera Group, including certification, to the best of a Party’s knowledge, of the accuracy and completeness of the information it has
supplied; and 
  

 20 

 (iii) the use of the Party’s commercially reasonable efforts to obtain any documentation that may
be necessary or reasonably helpful in connection with any of the foregoing. Each Party shall make its employees and facilities available on a reasonable and mutually convenient basis in connection with the foregoing matters. 
 (b) Retention of Records. Any Party that is in possession of documentation of Applera (or any Applera Affiliate) or Celera (or any Celera
Affiliate) relating to the Celera Business, including books, records, Tax Returns and all supporting schedules and information relating thereto (the “Celera Business Records”) shall retain such Celera Business Records for a period of seven
(7) years following the Exchange Date. Thereafter, any Party wishing to dispose of Celera Business Records in its possession (after the expiration of the applicable statute of limitations), shall provide written notice to the other Party
describing the documentation proposed to be destroyed or disposed of sixty (60) business days prior to taking such action. The other Party may arrange to take delivery of any or all of the documentation described in the notice at its expense
during the succeeding sixty (60) day period. 
 9.03. Dispute Resolution. Except with respect to Exchange Taxes, all disputes
under this agreement shall be controlled by Section 13.3 of the Separation Agreement. Notwithstanding the foregoing, any disagreement between the Parties relating to Exchange Taxes shall be settled in a court of law or as otherwise agreed to by
the Parties. 
 9.04. Notices. All notices and other communications required or permitted to be given hereunder shall be in writing
and shall be deemed given upon (a) a transmitter’s confirmation of a receipt of a facsimile transmission (but only if followed by confirmed delivery of a standard overnight courier the following business day or if delivered by hand the
following business day), (b) confirmed delivery of a standard overnight courier or when delivered by hand, or (c) the expiration of five (5) business days after the date mailed by certified or registered mail (return receipt
requested), postage prepaid, to the Parties at the following addresses (or at such other addresses for a Party as shall be specified by like notice): 
 If to Applera or any Applera Affiliate, to the Vice President, Tax of Applera, with a copy to the General Counsel of Applera, at: 
 Applera Corporation 
 301 Merritt 7 
 Norwalk, Connecticut 06851 
 If to Celera or any Celera Affiliate, to the General Counsel of Celera, at: 
 Celera Corporation 
 1401 Harbor Bay Parkway 
 Alameda, California 94502 
 Either Party may, by written notice to the other Parties, change the address or the Party to which any notice, request, instruction or other documents is
to be delivered. 
  

 21 

 9.05. Changes in Law. 
 (a) Any reference to a provision of the Code or a law of another jurisdiction shall include a reference to any applicable successor provision or law.

 (b) If, due to any change in applicable law or regulations or their interpretation by any court of law or other governing body having
jurisdiction subsequent to the date of this Agreement, performance of any provision of this Agreement or any transaction contemplated thereby shall become impracticable or impossible, the Parties hereto shall use their commercially reasonable
efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such provision. 
 9.06. Confidentiality. The Parties shall comply with the confidentiality provisions in section 13.9 of the Separation Agreement. 
 9.07. Successors. This Agreement shall be binding on and inure to the benefit and detriment of any successor, by merger, acquisition of assets or otherwise, to any of the Parties hereto, to the same extent as if such successor had
been an original party. 
 9.08. Affiliates. Applera shall cause to be performed, and hereby guarantees the performance of, all
actions, agreements and obligations set forth herein to be performed by any Applera Affiliate, and Celera shall cause to be performed, and hereby guarantees the performance of, all actions, agreements and obligations set forth herein to be performed
by any Celera Affiliate; provided, however, that (1) if it is contemplated that a Celera Affiliate may cease to be a Celera Affiliate as a result of a transfer of its stock or other ownership interests to a third party in exchange
for consideration in an amount approximately equal to the fair market value of the stock or other ownership interests transferred and such consideration is not distributed outside of the Celera Group to the shareholders of Celera then
(a) Celera shall request in writing no later than thirty (30) days prior to such cessation that Applera execute a release of such Celera Affiliate from its obligations under this Agreement effective as of such transfer provided that Celera
shall have confirmed in writing its obligations and the obligations of its remaining Celera Affiliates with respect to their own obligations and those of the departing Celera Affiliate and that such departing Celera Affiliate shall have executed a
release of any rights it may have against Applera or any Applera Affiliate by reason of this Agreement, or (b) Celera shall acknowledge in writing no later than thirty (30) days prior to such cessation that it shall bear one hundred
percent (100%) of the liability for the obligations of Celera and each Celera Affiliate (including the departing Celera Affiliate) under this Agreement and (2) if it is contemplated that an Applera Affiliate may cease to be an Applera
Affiliate as a result of a transfer of its stock or other ownership interests to a third party in exchange for consideration in an amount approximately equal to the fair market value of the stock or other ownership interests transferred and such
consideration is not distributed outside of the Applera Group to the shareholders of Applera then (a) Applera shall request in writing no later than thirty (30) days prior to such cessation that Celera execute a release of such Applera
Affiliate from its obligations under this Agreement effective as of such transfer provided that Applera shall have confirmed in writing its obligations and the obligations of its remaining Applera Affiliates with respect to their 

  

 22 

 
own obligations and the obligations of the departing Applera Affiliate and that such departing Applera Affiliate shall have executed a release of any rights
it may have against Celera or any Celera Affiliate by reason of this Agreement, or (b) Applera shall acknowledge in writing no later than thirty (30) days prior to such cessation that it shall bear one hundred percent (100%) of the
liability for the obligations of Applera and each Applera Affiliate (including the departing Applera Affiliate) under this Agreement. If at any time (1) Applera shall, directly or indirectly, obtain beneficial ownership of more than fifty
percent (50%) of the total combined voting power of any other entity, Applera shall cause such entity to become a party to this Agreement by executing together with Celera an agreement in substantially the same form as set forth in Schedule
9.08 and such entity shall have all rights and obligations of an Applera Affiliate under this Agreement, and (2) Celera shall, directly or indirectly, obtain beneficial ownership of more than fifty percent (50%) of the total combined
voting power of any other entity, Celera shall cause such entity to become a party to this Agreement by executing together with Applera an agreement in substantially the same form as set forth in Schedule 9.08 and such entity shall have all rights
and obligations of a Celera Affiliate under this Agreement. 
 9.09. Authorization, Etc. Each of the Parties hereto hereby represents
and warrants that it has the power and authority to execute, deliver and perform this Agreement, that this Agreement has been duly authorized by all necessary corporate action on the part of such Party, that this Agreement constitutes a legal, valid
and binding obligation of each such Party and that the execution, delivery and performance of this Agreement by such Party does not contravene or conflict with any provision of law or of its charter or bylaws or any agreement, instrument or order
binding on such Party. 
 9.10. Entire Agreement. This Agreement contains the entire agreement among the Parties hereto with respect
to the subject matter hereof and supersedes any prior tax sharing agreements between Applera (or any Applera Affiliate) and Celera (or any Celera Affiliate) and such prior tax sharing agreements shall have no further force and effect. If, and to the
extent, the provisions of this Agreement conflict with any agreement entered into in connection with the Split-Off, the provisions of this Agreement shall control. 
 9.11. Applicable Law; Jurisdiction. EACH OF THE PARTIES TO THIS AGREEMENT HEREBY IRREVOCABLY AND UNCONDITIONALLY (i) AGREES THAT THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND ALL DISPUTES
CONTROVERSIES OR CLAIMS ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE BREACH, TERMINATION OR VALIDITY HEREOF SHALL BE GOVERNED BY THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ITS CONFLICTS OF LAW RULES, (ii) AGREES TO BE SUBJECT TO, AND
HEREBY CONSENTS AND SUBMITS TO, THE JURISDICTION OF THE COURTS OF THE STATE OF DELAWARE AND OF THE FEDERAL COURTS SITTING IN THE STATE OF DELAWARE, (iii) TO THE EXTENT SUCH PARTY IS NOT OTHERWISE SUBJECT TO SERVICE OF PROCESS IN THE STATE OF
DELAWARE, HEREBY APPOINTS THE CORPORATION TRUST COMPANY, AS SUCH PARTY’S AGENT IN THE STATE OF DELAWARE FOR ACCEPTANCE OF LEGAL PROCESS, AND (iv) AGREES THAT SERVICE MADE ON ANY SUCH AGENT SET FORTH IN (iii) ABOVE SHALL HAVE 

  

 23 

 
THE SAME LEGAL FORCE AND EFFECT AS IF SERVED UPON SUCH PARTY PERSONALLY WITHIN THE STATE OF DELAWARE. 
 9.12. Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same Agreement. 
 9.13. Severability. If any term, provision, covenant, or restriction of this
Agreement is held by a court of competent jurisdiction (or an arbitrator or arbitration panel) to be invalid, void, or unenforceable, the remainder of the terms, provisions, covenants, and restrictions set forth herein shall remain in full force and
effect, and shall in no way be affected, impaired, or invalidated. In the event that any such term, provision, covenant or restriction is held to be invalid, void or unenforceable, the Parties hereto shall use commercially reasonable efforts to find
and employ an alternate means to achieve the same or substantially the same result as that contemplated by such terms, provisions, covenant, or restriction. 
 9.14. No Third Party Beneficiaries. This Agreement is solely for the benefit of Applera, the Applera Affiliates, Celera and the Celera Affiliates. This Agreement should not be deemed to confer upon third
parties any remedy, claim, liability, reimbursement, cause of action or other rights in excess of those existing without this Agreement. 
 9.15. Waivers, Etc. No failure or delay on the part of a Party in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such right or power, preclude any other or further exercise thereof or the exercise of any other right or power. No modification or waiver of any provision of this Agreement nor consent to any departure by the
Parties therefrom shall in any event be effective unless the same shall be in writing, and then such waiver or consent shall be effective only in the specific instance and for the purpose for which given. 
 9.16. Setoff. All payments to be made by any Party under this Agreement may be netted against payments due to such Party under this Agreement, but
otherwise shall be made without setoff, counterclaim or withholding, all of which are hereby expressly waived. 
 9.17. Other
Remedies. Celera recognizes that any failure by it or any Celera Affiliate to comply with its obligations under Section 4 could result in Exchange Taxes that would cause irreparable harm to Applera, Applera Affiliates, and their
stockholders. Accordingly, Applera shall be entitled to an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement, this being in addition to any other remedy to which
Applera is entitled at law or in equity. 
 9.18. Amendment and Modification. This Agreement may be amended, modified or supplemented
only by a written agreement signed by all of the Parties hereto. 
 9.19. Waiver of Jury Trial. Each of the Parties hereto irrevocably
and unconditionally waives all right to trial by jury in any litigation, claim, action, suit, arbitration, inquiry, 

  

 24 

 
proceeding, investigation or counterclaim (whether based in contract, tort or otherwise) arising out of or relating to this Agreement or the actions of the
Parties hereto in the negotiation, administration, performance and enforcement thereof. 
 9.20. Interpretations. The headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Whenever the words “include,” “includes” or “including” are used in this
Agreement they shall be deemed to be followed by the words “without limitation.” The words “hereof,” “herein” and “herewith” and words of similar import shall, unless otherwise stated, be construed to refer to
this Agreement as a whole and not to any particular provision of this Agreement, and article, section, paragraph, Exhibit and schedule references are to the articles, sections, paragraphs, exhibits and schedules of this Agreement unless otherwise
specified. The meaning assigned to each term defined herein shall be equally applicable to both the singular and the plural forms of such term, and words denoting any gender shall include all genders. Where a word or phrase is defined herein, each
of its other grammatical forms shall have a corresponding meaning. The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement
shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement. 
  

 25 

 IN WITNESS WHEREOF, each of the Parties hereto has caused this Agreement to be executed by a duly
authorized officer as of the date first above written. 
  

			
	 Applera Corporation
 on behalf of itself and
each of the Applera Affiliates

		
	By:	 	/s/ Mark P. Stevenson
	Name:	 	Mark P. Stevenson
	Title:	 	Senior Vice President

  
  

			
	 Celera Corporation
 on behalf of itself and
each of the Celera Affiliates

		
	By:	 	/s/ Kathy Ordoñez
	 Name:
	 	Kathy Ordoñez
	 Title:
	 	President and CEOOperating Agreement dated as of July 1, 2008

 Exhibit 10.36.3 
  
 EXECUTION COPY 
  
  
  
 OPERATING AGREEMENT 
  
 BY AND BETWEEN 
  
 APPLERA CORPORATION 

 
 AND 
  
 CELERA CORPORATION 
  
  
  
  
 DATED AS OF JULY 1, 2008 
  
  
 [***] indicates material that has been omitted pursuant to a request for confidential treatment. The omitted material has been filed separately with the Securities and
Exchange Commission. 

 TABLE OF CONTENTS 
  

			
	 ARTICLE I DEFINITIONS
	  	2
		
	 Section 1.1 Definitions
	  	2
		
	 ARTICLE II GENERAL
	  	4
		
	 Section 2.1 Performance
	  	4
		
	 Section 2.2 General Cooperation
	  	4
		
	 Section 2.3 Research and Development Activities
	  	4
		
	 ARTICLE III OPERATING PRINCIPLES
	  	4
		
	 Section 3.1 Capillary Electrophoresis Sequencers
	  	4
		
	 Section 3.2 Kauai Project
	  	5
		
	 Section 3.3 Next Generation Sequencing Technology
	  	6
		
	 Section 3.4 Real-Time Instruments
	  	6
		
	 Section 3.5 Reagents
	  	8
		
	 Section 3.6 Maui Project
	  	9
		
	 Section 3.7 Licenses and Licensing
	  	10
		
	 Section 3.8 Applera Intellectual Property.
	  	10
		
	 Section 3.9 Application of Restrictions in Event of Acquisitions
	  	11
		
	 Section 3.10 Use and Restrictions of Confidential Information, Know-How and Trade Secrets.
	  	11
		
	 ARTICLE IV RELATIONSHIP TO OTHER DOCUMENTS
	  	13
		
	 ARTICLE V DISPUTE RESOLUTION
	  	13
		
	 ARTICLE VI INDEMNIFICATION
	  	13
		
	 ARTICLE VII FORCE MAJEURE
	  	13
		
	 ARTICLE VIII TERMINATION
	  	13
		
	 Section 8.1 Termination
	  	13
		
	 Section 8.2 Termination for Default
	  	13

  

 i 

			
	 Section 8.3 Return or Destruction of Material
	  	14
		
	 Section 8.4 Effect of Termination
	  	14
		
	 ARTICLE IX OTHER REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	14
		
	 Section 9.1 Compliance with Laws
	  	14
		
	 Section 9.2 Books and Records
	  	14
		
	 Section 9.3 No Other Representations or Warranties
	  	14
		
	 ARTICLE X MISCELLANEOUS
	  	15
		
	 Section 10.1 Relationship of the Parties
	  	15
		
	 Section 10.2 Employees of the Parties
	  	15
		
	 Section 10.3 Notices
	  	15
		
	 Section 10.4 Governing Law
	  	16
		
	 Section 10.5 Parties in Interest; Assignment; Successors
	  	16
		
	 Section 10.6 Entire Agreement
	  	16
		
	 Section 10.7 Exhibits
	  	16
		
	 Section 10.8 Waivers of Default
	  	16
		
	 Section 10.9 Amendments
	  	16
		
	 Section 10.10 Headings
	  	17
		
	 Section 10.11 Severability; Enforcement
	  	17
		
	 Section 10.12 No Third-Party Beneficiaries
	  	17
		
	 Section 10.13 Remedies
	  	17
		
	 Section 10.14 Expenses
	  	17
		
	 Section 10.15 Counterparts
	  	17
		
	 Section 10.16 No Set-Off
	  	17
		
	 Section 10.17 Confidentiality
	  	17
		
	 Section 10.18 Facilities and Systems Security
	  	17

 Exhibit A – Definition of HIVD Field 
 Exhibit B – Specified Country List 
 Exhibit C – Forensics and Applied Markets 
  

 ii 

 OPERATING AGREEMENT 
 This Operating Agreement (this “Agreement”), dated as of July 1, 2008 (the “Effective Date”), by and between Applera Corporation, a Delaware corporation
(“Applera”), and Celera Corporation, a Delaware corporation (“Celera” and, collectively with Applera, the “Parties,” and each individually, a “Party”). 
 R E C I T A L S 
 WHEREAS, prior to the Separation (as defined below) Applera conducted its business through two business segments – the Applied Biosystems Group, which primarily serves the life science industry, research community and other markets,
including human identity testing, biosecurity, and quality and safety testing, by developing and marketing instrument-based systems, consumables, software, and services (the “Applied Biosystems Business”), and the Celera Group,
which is primarily a human in vitro diagnostics business that delivers personalized disease management through a combination of products and services (the “Celera Business”); and 
 WHEREAS, the Board of Directors of Applera has determined that it is advisable and in the best interests of Applera and its stockholders to separate the
Celera Group from Applera by way of a redemption of all of the issued and outstanding Celera Group Common Stock pursuant to Article IV, Section 2.4(d) of Applera’s Restated Certificate of Incorporation (the “Separation”),
so that, from and after the date hereof, the Celera Business will be conducted through Celera, which will be a separate, independent publicly traded company; and 
 WHEREAS, to effectuate the Separation, the Parties have entered into that certain Separation Agreement dated as of May 8, 2008 (the “Separation Agreement”) setting forth, among other things, the
terms and conditions of the Separation (capitalized terms used herein but not defined herein shall have the meanings set forth in the Separation Agreement); and 
 WHEREAS, in connection with the Separation, Applera intends to effect a name change from Applera Corporation to Applied Biosystems Inc.; and 
 WHEREAS, in connection with the Separation, Applera and Celera desire to enter into this Agreement to memorialize their mutual understanding and
agreement with respect to the conduct of certain aspects of their businesses following the date hereof. 
 NOW, THEREFORE, in consideration
of the premises and the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound hereby, agree as
follows: 
  

 1 

 ARTICLE I 
 DEFINITIONS 
 Section 1.1 Definitions. For purposes of this Agreement, the following
terms shall have the meanings set forth below: 
 (a) “Abbott Alliance” means the strategic alliance among Abbott
Laboratories, Applera, and Celera Diagnostics, LLC, pursuant to the Abbott Alliance Agreement. 
 (b) “Abbott Alliance
Agreement” means the Restated Strategic Alliance Agreement, effective as of January 9, 2006, among Applera, Celera Diagnostics, LLC, and Abbott Laboratories. 
 (c) “Abbott Supply Agreement” means the Abbott Real-Time PCR Instrument Supply Agreement, effective as of September 14, 2004,
between Applera and Abbott Laboratories. 
 (d) “ASR” means an analyte specific reagent as defined under 21 CFR
§864.4020(a), as the same may be amended or replaced from to time. 
 (e) “CE” means capillary electrophoresis.

 (f) “CE-Marked” means CE marking in accordance with the In Vitro Diagnostics Directive (IVDD) 98/79/EC. 
 (g) “CE Assays” means consumable products used on CE sequencers for HIV genotyping, HCV genotyping, HBV genotyping, CF, Fragile X, and
HLA typing assays for the analysis of nucleic acids in the HIVD Field. 
 (h) “CF” means cystic fibrosis. 
 (i) “CT” means Chlamydia trachomatis. 
 (j) “Factor II” means prothrombin, a protein involved in blood clotting, and the gene that encodes it or a variant thereof. 
 (k) “Factor V” means a protein involved in blood clotting, and the gene that encodes it or a variant thereof, such as factor V Leiden.

 (l) “Fragile X” means Fragile X syndrome. 
 (m) “GPR” or “General Purpose Reagent” means a chemical or biological reagent that (i) is not an ASR and (ii) has general laboratory application. 
 (n) “Group” means either the Applied Biosystems Group or the Celera Group. 
 (o) “[***]” means [***]. 
 (p)
“HBV” means hepatitis B virus. 
  

 2 

 (q) “HCV” means hepatitis C virus. 
 (r) “HIV” means human immunodeficiency virus. 
 (s) “HIVD Field” means the field of human in vitro diagnostics as defined on Exhibit A attached hereto. 
 (t) “HLA” means human leukocyte antigen. 
 (u) “[***]” means [***]. 

(v) “Kauai Project” means the Celera instrument development project code-named “Kauai” by the Parties for internal
reference purposes. 
 (w) “Licensed IP” means any Applera intellectual property previously licensed by Celera under the
terms of (i) the Real-Time Instrument Patent License Agreement, effective as of April 5, 2004, between Applera and Cepheid, (ii) the Real-Time Instrument Patent License Agreement, effective as of April 25, 2006, and Diagnostics
Field DNA Sequencing Sublicense Agreement, effective as of April 25, 2006, between Applera and Beckman Coulter, Inc., or (iii) the License Agreement, effective as of July 1, 2007, and Sequence Analysis License Agreement, effective as
of April 20, 2000, between Applera and Siemens Medical Solutions Diagnostics. 
 (x) “Maui Assays” means consumable
products resulting from the Maui Project for HIV genotyping, HCV genotyping, HBV genotyping, CF, Fragile X, and HLA typing assays for the analysis of nucleic acids in the HIVD Field. 
 (y) “Maui Project” means the Applera instrument development project code-named “Maui” by the Parties for internal reference
purposes. 
 (z) “[***]” means [***]. 
 (aa) “NG” means Neisseria gonorrhoeae. 
 (bb) “OEM” means a supply
arrangement whereby Applera supplies a product to a third party that (i) is not a distributor, agent or wholesaler for Applera, and (ii) resells such product. A specific example of a company that is not a distributor, agent or wholesaler
for Applera is a company that commercializes diagnostic products globally. 
 (cc) “Real-Time Assays” means real-time
PCR-based assays for the analysis of nucleic acids of HIV, HCV, HBV, [***], CT, NG, [***], and [***] in the HIVD Field. 
 (dd)
“Real-Time Instrument” means a real-time PCR thermal cycler covered by the claims of US Patent No. 6,814,934. 
 (ee)
“Specified Countries” means the countries and territories, as commonly recognized as of the Effective Date, including any such country and territory as may be 

  

 3 

 
subsequently recognized by a different name, set forth on the “Specified Country List” attached hereto as Exhibit B. 
 (ff) “Specified Supplier” means [***]. 
 (gg) “Supply Agreement” means that certain Master Purchase Agreement between the Parties of even date with this Agreement pursuant to which Applera is to supply certain products to Celera. 

ARTICLE II 
 GENERAL 

 Section 2.1 Performance. Applera and Celera hereby agree that each Party shall use commercially reasonable efforts to take, or
cause to be taken, all actions, and to do, or cause to be done, all things necessary, proper or advisable under applicable laws to comply with the terms of this Agreement, including the operating principles set forth in Article III hereof.

 Section 2.2 General Cooperation. Subject to the terms and conditions set forth in this Agreement, Applera and Celera shall each use
commercially reasonable efforts to provide to the other Party any information and documentation reasonably required in the performance of such other Party’s obligations hereunder, and make available, as reasonably requested by the other Party,
sufficient resources and timely decisions, approvals and acceptances in order that each Party may fulfill its obligations under this Agreement in a timely and efficient manner. 
 Section 2.3 Research and Development Activities. Applera and Celera agree that (i) the human in vitro diagnostics business of Celera includes
research and development activities toward commercialization of products and services in the HIVD Field and (ii) the restrictions imposed on Applera pursuant to this Agreement shall not prevent Applera from conducting its own research and
development activities in the HIVD Field at any time during the term of this Agreement. 
 ARTICLE III 
 OPERATING PRINCIPLES 
 Section
3.1 Capillary Electrophoresis Sequencers 
 (a) Abbott Alliance. From and after the Effective Date, Applera shall provide to
Abbott Laboratories (“Abbott”), as provided for in the Abbott Alliance Agreement, and/or Celera the current (as of the Effective Date) CE sequencers of Applera and associated consumables, in each case, as they have been provided by
Applera to Abbott and/or Celera in connection with the Abbott Alliance prior to the Effective Date or as otherwise provided under a separate supply agreement between Applera and Celera. 
 (b) Rights of Celera. From and after the Effective Date and to the extent not otherwise provided to Abbott and/or Celera, Applera shall provide
Celera with CE sequencers and associated consumables in the same manner as provided to other third party customers of 

  

 4 

 
Applera. In the event that Celera wishes to purchase CE sequencers developed by Applera but not otherwise offered for sale, the Parties shall negotiate in
good faith the terms and conditions of such access. 
 (c) Restrictions on Celera 
 (i) Celera shall purchase CE sequencers described in (a) and (b), above, and associated consumables, pursuant to the Supply
Agreement. 
 (ii) Celera may only sell such CE sequencers and associated consumables in the HIVD Field. 
 (d) Rights of Applera. Applera may: 
  

	 	(i)	sell any CE sequencer to any end-user for any purpose; and 

  

	 	(ii)	OEM any CE sequencer to any customer (an “OEM Customer”) for any purpose; provided, however, that any such OEM Customer shall agree that it shall not
commercialize any CE Assay on such CE sequencer in any country or territory other than the Specified Countries for a period of three (3) years following the Effective Date, subject to Section 3.9(c) hereof. 

 (e) Restrictions on Applera. Applera shall not: 
  

	 	(i)	[***]; 

  

	 	(ii)	commercialize any CE Assay for a period of three (3) years following the Effective Date, subject to Section 3.9 hereof; or 

  

	 	(iii)	enter into an agreement with a third party to co-promote or co-market CE sequencers to be used with CE Assays, in any country or territory other than the Specified Countries for a
period of three (3) years following the Effective Date, subject to Section 3.9 hereof. 

 Section 3.2 Kauai
Project. 
 (a) Project Development. Celera may develop products under the Kauai Project that comply with the requirements of the
United States Food and Drug Administration (the “FDA”), and shall pay all costs associated with meeting such requirements. Celera and Applera shall enter into good faith negotiations to conclude an agreement regarding the Kauai
Project, on mutually agreed upon terms, covering, among other things, support of Celera’s development activities (“Kauai Agreement”). 
  

 5 

 (b) Kauai Products. 
  

	 	(i)	The products resulting from the Kauai Project shall be intended for use in the HIVD Field, but not intended for use outside the HIVD Field. 

  

	 	(ii)	Celera shall be the manufacturer of record for products resulting from the Kauai Project. 

  

	 	(iii)	Products resulting from the Kauai Project may only be sold by Celera and only for use in the HIVD Field. 

  

	 	(iv)	Except as otherwise agreed by the Parties, Applera shall not sell any instrument resulting from the Kauai Project. 

 (c) Access to Specified Supplier. Applera agrees to use commercially reasonable efforts to facilitate Celera access to the Specified Supplier for
the purpose of development and commercialization of products under the Kauai Project. 
  

	 	(i)	In the event that Celera is legally required to source products resulting from the Kauai Project directly from the Specified Supplier, it shall be permitted to do so, and in such
event Applera shall be entitled to receive compensation from Celera in an amount equal to the amount of incremental proceeds Applera would have received had the products been sourced directly from it. The amount of such incremental proceeds would be
calculated in accordance with the provisions of the Kauai Agreement. 

 Section 3.3 Next Generation Sequencing
Technology. It is the intent and mutual understanding of the Parties that this Agreement shall not constitute or be deemed to constitute any commitment or obligation for the Parties to collaborate on any “next generation” sequencing
instrument. Specifically, this Agreement places no restrictions whatsoever on either Party relating to the development or commercialization of next generation sequencing instruments. 
 Section 3.4 Real-Time Instruments. 
 (a) Real-Time Instruments. 
  

	 	(i)	Except for the restrictions under the Abbott Supply Agreement in effect as of the Effective Date or as such agreement may be amended by the parties to that agreement with
Celera’s approval (not to be unreasonably withheld or delayed), Applera shall be permitted to sell Real-Time Instruments, including instruments registered with a regulatory authority, to any end user for any purpose; and

  

 6 

	 	(ii)	Except for the Abbott Supply Agreement in effect as of the Effective Date or as such agreement may be amended by the parties to that agreement with Celera’s approval (not to be
unreasonably withheld or delayed), Applera shall not OEM Real-Time Instruments to any OEM Customer for use in the HIVD Field unless such OEM Customer has obtained a license to the relevant Licensed IP for real-time technology in the HIVD Field;
provided, however, that any such OEM Customer shall also agree that it shall not commercialize any Real-Time Assay on such Real-Time Instruments, unless otherwise agreed to by Applera and Celera, for a period of three (3) years
following the Effective Date, subject to Section 3.9(c) hereof. 

  

	 	(iii)	Applera shall not enter into an agreement with a third party to co-promote or co-market Real-Time Instruments to be used with Real-Time Assays, in any country or territory other
than the Specified Countries for a period of three (3) years following the Effective Date, subject to Section 3.9 hereof. 

 (b) Preferred Supplier Designation. Applera will be the preferred supplier of Celera’s next generation Real-Time Instrument, subject to the following terms and conditions: 
  

	 	(i)	The Parties agree to negotiate in good faith the terms of a supply agreement for such instrument; and 

  

	 	(ii)	If, after negotiating in good faith, the Parties are unable to enter into such supply agreement within [***] following receipt of a notice from Celera specifying the date on which
the Parties shall commence such negotiation (which date may not be prior to the date of the notice), the Parties may agree to a [***] extension. If the Parties are unable or unwilling to agree to an extension or if no agreement is reached during any
such extension, Celera shall be granted [***] to all intellectual property owned by Applera and all intellectual property which Applera has the right to sublicense (and Celera shall bear the cost of any pass through royalties that would be
associated with that sublicense) as of the Effective Date that is necessary to make or to have a next generation Real-Time Instrument made and supplied by a third party only to Celera; provided, however, that the terms of any such
third-party supply relationship shall be no less favorable to Celera than the terms last proposed by Applera; and, provided further, that such third party shall not be infringing or challenging any patents of Applera related to such next
generation real-time instruments at the time when Celera enters into a supply agreement with such third party. 

  

 7 

 Section 3.5 Reagents. 
 (a) Sequence Specific Primers and Probes. Applera agrees that it will not knowingly commercialize any sequence-specific primers and probes
(i) for incorporation by a third party product manufacturer into its products for performing testing in the HIVD Field or (ii) to a clinical laboratory for performing home-brew testing, in either case, for HIV, HCV, HBV, [***], CT, NG,
Factor V, Factor II, [***], CF, HLA, Fragile X, and [***], for a period of three (3) years following the Effective Date, subject to Section 3.9 hereof; provided, however, that: 
  

	 	(i)	Applera may request that Celera waive this restriction for Applera to commercialize such primers and probes during the three (3) year period following the Effective Date for
specific opportunities, it being understood that the decision to so waive this restriction shall be made by Celera in its sole discretion; 

  

	 	(ii)	Applera shall not be obligated to actively monitor third party conduct for any inadvertent violation, but Applera and Celera shall discuss an appropriate course of action upon
notice from Celera with reasonable evidence of violation of this provision or if Applera otherwise becomes aware of such a violation; and 

  

	 	(iii)	The restrictions set forth in this Section 3.5 shall not apply to sales to any third party for sale or use within any Specified Country. 

 (b) Analyte Specific Reagents (ASRs). Applera shall not commercialize, directly or through a distributor, ASRs or kits for performing human
testing in the HIVD Field for HIV, HCV, HBV, [***], CT, NG, Factor V, Factor II, [***], CF, HLA, Fragile X, and [***], for a period of three (3) years following the Effective Date, subject to Section 3.9 hereof. 
 (c) General Purpose Reagents (GPRs). This Agreement provides no restrictions or limitations on the ability of Applera to sell GPRs. 
 (d) Other Limitations. 
  

	 	(i)	Except for the rights granted pursuant to the HLA License Agreement, Applera shall not have any rights to Celera’s intellectual property assigned to it by Applera pursuant to
the Separation Agreement. In the event that Applera has a product that infringes Celera’s intellectual property, and upon notice from Celera with reasonable evidence of unlicensed activity, Applera shall stop selling such product. Applera may
resume sales of such product if Applera or its customers are no longer (or are not) infringing Celera’s intellectual property rights in the HIVD Field, unless otherwise prohibited herein. 

  

 8 

	 	(ii)	Celera shall not commercialize, directly or through a distributor, products in the forensics and applied markets listed on Exhibit C hereto that incorporate intellectual property
owned by Applera or which Applera has the exclusive right to sublicense, unless Celera obtains a license directly or indirectly to the relevant intellectual property from Applera under standard third party terms to be mutually agreed upon.

 Section 3.6 Maui Project. 
 (a) Project Development. Products developed by Applera under the Maui Project need not be submitted by Applera for registration with the FDA in the United States, but may be registered with any other regulatory
authority. Furthermore, it is understood by the Parties that any instrument developed under the Maui Project shall not be “Alliance Products” or “Alliance Technology” (as such terms are defined in the Abbott Alliance Agreement)
and shall be treated within the Abbott Alliance in the same manner as other similar products of Applera that are not “Alliance Products” or “Alliance Technology.” 
 (b) Rights of Applera. In connection with the Maui Project, Applera shall be free to: 
  

	 	(i)	sell any product resulting from the Maui Project to any end-user for any purpose; and 

  

	 	(ii)	OEM any product resulting from the Maui Project to any customer for any purpose; provided, however, that any such OEM Customer shall agree that it shall not
commercialize any Maui Assay in any country or territory other than the Specified Countries for a period of three (3) years following the Effective Date, subject to Section 3.9(c) hereof. 

 (c) Restrictions on Applera. In connection with the Maui Project, Applera shall not: 
  

	 	(i)	supply or OEM any instrument resulting from the Maui Project to Abbott other than through the Abbott Alliance; or 

  

	 	(ii)	commercialize the Maui Assays for a period of three (3) years following the Effective Date, subject to Section 3.9 hereof. 

 (d) Celera Rights and Restrictions. Celera may purchase products resulting from the Maui Project through the Supply Agreement. In addition, Celera
may only sell products resulting from the Maui Project for use in the HIVD Field. 
 (e) US FDA Cleared or Approved Version of Maui.
Applera agrees that if it obtains FDA clearance or approval on an instrument developed under the Maui Project in the United States, or any instrument that is substantially based on the design and throughput of an 

  

 9 

 
instrument developed under the Maui Project, it will make such FDA cleared or approved version of the Maui product available to Celera under the Supply
Agreement. 
 Section 3.7 Licenses and Licensing. 
 (a) Celera Licensing Rights. There shall be no restrictions on Celera’s ability to license any intellectual property assigned to Celera by Applera as of the Effective Date. 
 (b) Licensed Intellectual Property. Subject to the following conditions, Celera and Applera shall work together in good faith to license to third
parties the Licensed IP in the HIVD Field: 
  

	 	(i)	All such licenses shall be consistent with existing licenses to the Licensed IP; provided, however, that the terms of a new HIVD Field license to an existing non-HIVD
Field licensee shall use language and terms that do not conflict with the terms (especially definitions of fields) of the existing license to said licensee. 

  

	 	(ii)	Celera shall have primary responsibility for negotiation of the licenses, although Applera will be kept informed of, and have the right to participate in, all such negotiations.
Celera will provide Applera with reasonable prior notice of meetings, whether in person or by phone, with potential licensees. Celera will also provide Applera with reasonable time to review documents prior to sending them to potential licensees.

  

	 	(iii)	All revenue generated by such licenses shall be shared equally between Celera and Applera. 

  

	 	(iv)	The Parties have agreed on a list of approved licensees and a general framework for licenses. Transactions by either Party with such licensees and consistent with such general
framework shall not require any further approval of the other Party. Other licensees and/or changes from the framework shall require approval of both Parties. 

  

	 	(v)	From and after the Effective Date, Celera and Applera shall share costs associated with the Licensed IP, which costs include maintenance, prosecution, enforcement, and defense
costs, in such proportion as may be agreed by the Parties or as is necessary and appropriate to reflect the relative financial and other benefits received by each Party. Any disagreement regarding the allocation of such costs shall be resolved in
accordance with the dispute resolution procedures set forth in Article XIII of the Separation Agreement. 

 Section 3.8
Applera Intellectual Property. Except as otherwise provided herein, ownership of, and all rights in all fields to, Applera intellectual property shall remain with the 
  

 10 

 
Party that is the successor to the Group (including by way of name change) responsible for prosecuting or maintaining such intellectual property prior to the
Separation. 
 Section 3.9 Application of Restrictions in Event of Acquisitions. 
 (a) Acquisition of Competing Product. Notwithstanding any other provision hereof, the restrictions relating to assays described in Section 3
above do not apply to, and shall not restrict, on a product-by-product basis, the commercialization of an Existing Competing Product (as defined below) acquired as part of an acquisition of a third party or business by Applera or any Affiliate, nor
shall any such provision prohibit an acquirer of Applera from continuing to commercialize an Existing Competing Product following its acquisition of Applera. 
 (b) Definition of Existing Competing Product. For purposes of this Agreement, “Existing Competing Product” means a product that (i) a third party has: (w) commercialized on or before
the date of acquisition, or (x) submitted to a regulatory authority for approval or clearance on or before the date of acquisition, or (y) initiated clinical trials in connection with regulatory submission on or before the date of
acquisition, or (z) Quality System Regulation documentation showing that such product was in development before May 1, 2008 and (ii) is a CE Assay, Maui Assay, or Real-Time Assay. 
 (c) Use of Applera Technology. Notwithstanding any other provision hereof, in the event Applera is acquired by a third party and such acquirer
elects to produce a competing product that is not dependent on Applera technology, it will be free from any restrictions on such competing product under this Agreement. For the avoidance of doubt, the fact that an acquirer has obtained a license
under rights from Applera to make, have made, use and sell the competing product, but that the competing product is substantially the result of the design and development of the acquirer, shall not be construed for purposes herein as being
“dependent on Applera technology.” 
 Section 3.10 Use and Restrictions of Confidential Information, Know-How and Trade
Secrets. 
 (a) Any Information Known solely by one Group prior to the Effective Date (“Sole Information”) will be owned solely
by the Party that is the successor to that Group (including by way of name change) after the Effective Date. Neither Party shall be permitted to use or disclose Sole Information of the other Party, except to the extent that such Sole Information
(i) is or becomes generally available to the public, (ii) is independently developed after the Effective Date by the Party that did not Know such Information prior to the Effective Date, or (iii) becomes available after the Effective
Date to the Party that did not Know such Information prior to the Effective Date on a nonconfidential basis from a source other than the other Party, provided that such source is not subject to a confidentiality agreement or other obligation of
confidentiality to the other Party or any other Person with respect to any of such Information. For purposes of this Section 3.10(a), “Know” shall mean actual knowledge, as well as Information in a Party’s possession in written,
electronic or other tangible or intangible forms, stored in any medium. 
  

 11 

 (b) With respect to Information relating to the Celera Business or the Applied Biosystems Business that
is Known by both Groups (“Joint Information”), Celera’s use of such Joint Information after the Effective Date shall be limited to the HIVD Field. However, Celera may use or disclose to third parties for any purpose such Joint
Information primarily generated by the Celera Group using its resources prior to the Effective Date, except for those assets and businesses that have been transferred to the Applied Biosystems Group (including, by way of example, the assets
transferred by Celera to the Applied Biosystems Group related to the Celera Discovery System). If the Joint Information relates to the Applied Biosystems Business and was primarily generated by the Applied Biosystems Group using its resources prior
to the Effective Date, Celera may not disclose such Joint Information without the approval of Applera. For purposes of this Section 3.10(b), Joint Information shall not include Information that (i) is or becomes generally available to the
public other than through any act in violation of this Agreement by the Party seeking to use or disclose such Joint Information, (ii) is independently developed after the Effective Date by the Party seeking to use or disclose such Joint
Information, or (iii) becomes available after the Effective Date to the Party seeking to use or disclose such Joint Information on a nonconfidential basis from a source other than the other Party, provided that such source is not subject to a
confidentiality agreement or other obligation of confidentiality to the other Party or any other Person with respect to any of such Information. 
 (c) Applera shall not use or disclose Information that specifically relates to FDA requirements for registration of an instrument under the Kauai Project as of the Effective Date, that was primarily generated by the Celera Group using its
resources prior to the Effective Date, and that is Known by both Groups (the “FDA Information”). For purposes of this Section 3.10(c), FDA Information shall not include Information that (i) is or becomes generally available to
the public other than through any act of Applera in violation of this Agreement, (ii) is independently developed by Applera after the Effective Date, or (iii) becomes available to Applera after the Effective Date on a nonconfidential basis
from a source other than Celera, provided that such source is not subject to a confidentiality agreement or other obligation of confidentiality to Celera or any other Person with respect to any of such FDA Information. In addition, Applera shall not
use or disclose: (i) Celera’s Quality Manual and associated operating procedures for conformance to FDA’s Quality System Regulation; (ii) strategic plans of the Celera Business as presented by Celera’s executive management
to Applera’s executive management; or (iii) Celera’s diagnostic product designs and batch records. In the event that Applera elects to seek FDA registration for an instrument under the Maui Project, it shall make a good faith effort
to avoid using the Celera Group’s Kauai design and specifications required for FDA compliance that is Known to the Applied Biosystems Group prior to the Effective Date. Notwithstanding its use of good faith efforts, in the event Applera should
inadvertently use any of such Information specified in this Section 3.10(c), the Parties will discuss an appropriate course of action for such inadvertent use, prior to subjecting the matter to the Dispute Resolution Procedures set forth in
Article V of this Agreement. 
  

 12 

 ARTICLE IV 
 RELATIONSHIP TO OTHER DOCUMENTS 
 If there is any conflict or inconsistency between the terms
and conditions of this Agreement and the Separation Agreement, the provisions of this Agreement shall control solely with respect to the rights and obligations of the Parties set forth herein. 
 ARTICLE V 
 DISPUTE RESOLUTION 
 If a dispute arises between the Parties with respect to the terms and conditions of this Agreement, or any subject matter governed by this Agreement, the
Parties agree to use and follow the dispute resolution procedures set forth in Article XIII of the Separation Agreement to resolve any such dispute. 
 ARTICLE VI 
 INDEMNIFICATION 
 Each Party shall indemnify, defend and hold harmless the other Party, against and in respect of any and all Indemnifiable Losses that result from, relate to or arise out of this Agreement, to the extent and in the
manner set forth in Article XI of the Separation Agreement, except to the extent that any such Indemnifiable Losses arise out of or result from the gross negligence or willful misconduct of such other Party. 
 ARTICLE VII 
 FORCE MAJEURE

 No Party shall be in default of this Agreement to the extent that any delay or failure in the performance of its obligations under
this Agreement results from any cause beyond its reasonable control and without its fault or negligence, such as acts of God, acts of civil or military authority, embargoes, epidemics, war, riots, insurrections, fires, explosions, earthquakes,
floods, unusually severe weather conditions, power failures, communication failures including internet disruptions, equipment failures, labor problems or unavailability of parts. In the event of any such excused delay, the time for performance shall
be extended for a period equal to the time lost by reason of the delay. 
 ARTICLE VIII 
 TERMINATION 
 Section 8.1
Termination. This Agreement may be terminated at any time by the mutual written consent of the Parties. 
 Section 8.2 Termination
for Default. In the event: (i) either Party shall default, in any material respect, in the due performance or observance by it of any of the other terms, 
  

 13 

 
covenants or agreements contained in this Agreement or (ii) either Party shall become or be adjudicated insolvent and/or bankrupt, or a receiver or
trustee shall be appointed for either Party or its property or a petition for reorganization or arrangement under any bankruptcy or insolvency law shall be approved, or either Party shall file a voluntary petition in bankruptcy or shall consent to
the appointment of a receiver or trustee, the non-defaulting Party shall have the right, at its sole discretion, (A) in the case of a default under clause (ii), to immediately terminate this Agreement, and (B) in the case of a default
under clause (i), to terminate this Agreement if the defaulting Party has failed to (x) cure the default within thirty (30) days of written notice of default or if the default (except for defaults as a result of failure to make payment) is
such that it will take more than thirty (30) days to cure, within an extended time period which shall be not longer than what is reasonably necessary to effect performance or compliance or (y) diligently pursue the curing of the default.

 Section 8.3 Return or Destruction of Material. Upon termination of this Agreement, each of Applera and Celera will, and will cause
their respective Subsidiaries to, return or destroy any and all material and property of a proprietary nature involving the other Party and its Subsidiaries, in its possession or control, within thirty (30) days after the termination of this
Agreement. Notwithstanding anything to the contrary contained in this Agreement, upon the termination or expiration of this Agreement, Celera shall no longer be entitled to, and shall cease all access to Applera’s information, data, systems and
other assets that are not Celera Group Assets and Applera shall no longer be entitled to, and shall cease all access to Celera’s information, data, systems and other assets that are not Applied Biosystems Group Assets. 
 Section 8.4 Effect of Termination. The provisions of Section 3.10 and Articles IV, V, VI, VII, VIII and X shall survive the termination or
expiration of this Agreement. 
 ARTICLE IX 
 OTHER REPRESENTATIONS, WARRANTIES AND COVENANTS 
 Section 9.1 Compliance with Laws.
Each Party shall comply, at its own expense, with the provisions of all laws applicable to the performance of its obligations under this Agreement. 
 Section 9.2 Books and Records. Each Party or its Affiliates will maintain books and records substantially similar to those maintained prior to the date hereof pertaining to that portion of the Applera businesses attributable to such
Party. Each Party or its Affiliates will provide the other Party with access to such books and records in accordance with the provisions of Section 9.2 of the Separation Agreement. All such information shall be subject to the terms of the
confidentiality provisions set forth in Section 9.6 of the Separation Agreement. 
 Section 9.3 No Other Representations or
Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER PARTY NOR ANY OTHER PERSON MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY ON BEHALF OF EITHER PARTY WITH RESPECT TO THE
APPLERA BUSINESSES, AT LAW OR IN EQUITY, 

  

 14 

 
INCLUDING, WITHOUT LIMITATION, WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, AND ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES ARE
HEREBY EXPRESSLY DISCLAIMED. 
 ARTICLE X 
 MISCELLANEOUS 
 Section 10.1 Relationship of the Parties. The Parties declare and agree
that each Party is engaged in a business that is independent from that of the other Party and each Party shall perform its obligations as an independent contractor. It is expressly understood and agreed that Celera and Applera are not partners or
joint venturers, and nothing contained herein is intended to create an agency relationship or a partnership or joint venture. Neither Applera nor any of its Affiliates is an agent of Celera or any of its Affiliates and has no authority to represent
Celera or any of its Affiliates as to any matters, except as provided in Section 3.2(c) of this Agreement or in writing by Celera from time to time. Neither Celera nor any of its Affiliates is an agent of Applera or any of its Affiliates and
has no authority to represent Applera or any of its Affiliates as to any matters, except as authorized in this Agreement or in writing by Applera from time to time. 
 Section 10.2 Employees of the Parties. Applera shall be solely responsible for payment of compensation to its employees and for any injury to them in the course of their employment. Applera shall assume full
responsibility for payment of all federal, state and local taxes or contributions imposed or required under unemployment insurance, social security and income tax laws with respect to such persons. Celera shall be solely responsible for payment of
compensation to its employees and for any injury to them in the course of their employment. Celera shall assume full responsibility for payment of all federal, state and local taxes or contributions imposed or required under unemployment insurance,
social security and income tax laws with respect to such persons. 
 Section 10.3 Notices. All notices, requests, demands, waivers and
communications required or permitted to be given under this Agreement shall be in writing (which shall include notice by telecopy or like transmission) and shall be deemed given (i) on the day delivered (or if that day is not a Business Day, on
the first following Business Day) when (x) delivered personally against receipt or (y) sent by overnight courier, (ii) on the day when transmittal confirmation is received if sent by telecopy (or if that day is not a Business Day, on
the first following Business Day) and (iii) on the third Business Day after mailed by certified or registered first-class mail to the Parties at the following addresses (or to such other addresses as a Party may have specified by notice given
to the other Party hereto pursuant to this provision): 
 If to Applera, to: 
 Applera Corporation 
 301 Merritt 7 
 Norwalk, Connecticut 06851 
 Attention: General Counsel 
 Facsimile: (203) 840-2902 
  

 15 

 With a copy to: 
 Applied Biosystems 
 850 Lincoln Centre Drive 
 Foster City, California 94404 
 Attention: Vice President Intellectual Property 
 Facsimile: (650) 638-6677 
 If to Celera, to: 
 Celera Corporation 
 1401 Harbor Bay Parkway 
 Alameda, California 94502 
 Attention: President 
 Facsimile: (510) 749-4267 
 Section 10.4 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of Delaware, without reference to choice of law principles, including matters of construction, validity and performance.

 Section 10.5 Parties in Interest; Assignment; Successors. Neither this Agreement nor any of the rights, interests or obligations
hereunder shall be assigned by any of the Parties hereto (other than to a successor of either Party by way of merger, consolidation, sale of all or substantially all of such Party’s assets or similar transaction) without the prior written
consent of the other Parties. Subject to the preceding sentence, this Agreement shall inure to the benefit of and be binding upon Celera and Applera and their respective Subsidiaries, successors and permitted assigns. Nothing in this Agreement,
express or implied, is intended to confer upon any other Person any rights or remedies under or by reason of this Agreement. 
 Section 10.6
Entire Agreement. This Agreement, including the schedules, appendices, certificates, instruments and agreements delivered pursuant hereto, contain the entire understanding of the Parties hereto and thereto with respect to the subject matter
contained herein and therein, and supersede and cancel all prior agreements, negotiations, correspondence, undertakings and communications of the Parties, oral or written, respecting such subject matter. 
 Section 10.7 Exhibits. All exhibits referenced in this Agreement and attached hereto are incorporated into this Agreement by reference and made a
part hereof. 
 Section 10.8 Waivers of Default. Waiver by any Party of any default by any other Party of any provision of this
Agreement (a) shall be effective only if in writing; and (b) if given, shall not be deemed a waiver by the waiving Party of any subsequent or other default, nor shall it prejudice the rights of the other Party. 
 Section 10.9 Amendments. No provisions of this Agreement shall be deemed amended, supplemented or modified by any Party, unless such amendment,
supplement or 

  

 16 

 
modification is in writing and signed by the authorized representative of the Party against whom such waiver, amendment, supplement or modification is sought
to be enforced. 
 Section 10.10 Headings The article, section and paragraph headings contained in this Agreement are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement. All references herein to “Articles” or “Sections” shall be deemed to be references to Articles or Sections hereof unless otherwise
indicated. 
 Section 10.11 Severability; Enforcement. The invalidity of any portion hereof shall not affect the validity, force or
effect of the remaining portions hereof. If it is ever held that any restriction hereunder is too broad to permit enforcement of such restriction to its fullest extent, each Party agrees that a court of competent jurisdiction may enforce such
restriction to the maximum extent permitted by law, and each Party hereby consents and agrees that such scope may be judicially modified accordingly in any proceeding brought to enforce such restriction. 
 Section 10.12 No Third-Party Beneficiaries. Nothing in this Agreement shall confer any rights upon any Person or entity other than the Parties and
their respective heirs, successors and permitted assigns. 
 Section 10.13 Remedies. The Parties agree that money damages or other
remedy at law would not be a sufficient or adequate remedy for any breach or violation of, or a default under, this Agreement by them and that in addition to all other remedies available to them, each of them shall be entitled to the fullest extent
permitted by law to an injunction restraining such breach, violation or default or threatened breach, violation or default and to any other equitable relief, including specific performance, without bond or other security being required. 

Section 10.14 Expenses. Except as otherwise provided in this Agreement, the Parties shall bear their own expenses (including all time and
expenses of counsel, financial advisors, consultants, actuaries and independent accountants) incurred in connection with this Agreement. 
 Section 10.15 Counterparts. This Agreement may be executed in one or more counterparts, which may be delivered by facsimile or scanned electronic copy in pdf format, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. 
 Section 10.16 No Set-Off. The obligations under this Agreement shall not be
subject to set-off for non-performance or any monetary or non-monetary claim by any Party or any of their respective Affiliates under any other agreement between the Parties or any of their respective Affiliates. 
 Section 10.17 Confidentiality. Disclosure and use of Confidential Information by the Parties shall be governed by Section 9.6 of the
Separation Agreement and Section 3.10 of this Agreement. 
 Section 10.18 Facilities and Systems Security. If either Party or its
personnel shall be given access to the other Party’s facilities, premises, equipment or systems, such Party 

  

 17 

 
shall comply with all such other Party’s written security policies, procedures and requirements made available by each Party to the other, and shall not
tamper with, compromise, or circumvent any security or audit measures employed by such other Party. Each Party shall use its reasonable best efforts to ensure that only those of its personnel who are specifically authorized to have access to the
facilities, premises, equipment or systems of the other Party gain such access, and to prevent unauthorized access, use, destruction, alteration or loss in connection with such access. 
 [SIGNATURE PAGE FOLLOWS] 
  

 18 

 IN WITNESS WHEREOF, the Parties hereto have executed and delivered this Agreement as of the date first
above written. 
  

			
	APPLERA CORPORATION
		
	By:	 	/s/    Mark P. Stevenson        
		 	 Name: Mark P. Stevenson
 Title: Senior Vice President

  

			
	CELERA CORPORATION
		
	By:	 	/s/    Kathy Ordoñez
		 	 Name: Kathy Ordoñez
 Title: President and CEO

 Signature Page to Operating Agreement 

 Exhibit A 
 Definition of HIVD Field 
 Human In Vitro Diagnostics Field. The phrase
“Human In Vitro Diagnostics Field” shall mean the field of use comprising products, technologies, services and/or processes for use in the measurement, observation or determination of attributes, characteristics, diseases, traits or other
conditions of a human being: 
  

	 	•	 	 for the medical management of a human being; and/or 

	 	•	 	 for quality control or testing of human blood or tissue for transfusion or blood banking, bone marrow transplantation or banking, or tissue typing for
transplantation (where “banking” refers to human samples that are stored in anticipation of future implantation into the donor or transplantation into another human recipient). 

 Examples of activities in the HIVD Field: 
  

	 	•	 	 Development, manufacture, or sale of anything labeled for in vitro diagnostic use or any testing products labeled for investigational use;

	 	•	 	 Development, manufacture, or sale of products designated as Analyte Specific Reagents (ASRs) by FDA or corresponding reagent products in foreign regulatory
jurisdictions and general purpose reagents (GPRs) that are specifically sold for use with ASRs or such reagent products; 

	 	•	 	 Development or sale of software products for the interpretation of data to provide an HIVD clinical test result; 

	 	•	 	 Development, manufacture, or sale of products that convey amplification, sequencing, or other patent rights in the HIVD Field, or products that are designated
specifically for use with products that convey amplification, sequencing, or other patent rights in the HIVD Field; 

	 	•	 	 Genetic testing for sample tracking in a clinical laboratory; 

	 	•	 	 Sale of any in vitro testing products regulated by the FDA, including products claimed to be produced under Quality System Regulation to be sold to IVD
companies or clinical testing laboratories; 

	 	•	 	 In- and out-licensing or other transfer of patents, technology, or know-how for HIVD use (including any accompanying contract manufacture of custom reagents for
specific diagnostic customers’ homebrew testing, whether or not the reagents are produced under Quality System Regulation); 

	 	•	 	 Development, manufacture, or sale of, or providing service and support for, systems (reagents, components and/or instruments) developed and manufactured for HIVD
use or developed specifically for use with ASRs (or their counterparts outside the US); and 

	 	•	 	 Provision of HIVD testing services. 

 Examples of
activities not in the HIVD Field: 
  

 1 

	 	•	 	 Development, manufacture, or sale of products or services for basic and applied research, including clinical research where the medical management of a patient is
not involved, unless the product or service is regulated as an in vitro diagnostic test or ASR by the FDA or its foreign counterparts; 

	 	•	 	 Development, manufacture, or sale of products or services for quality assurance and quality control, including testing to determine conformance with specifications,
purity and batch-to-batch consistency, but excluding human plasma or tissue-derived samples for the pharmaceutical industry; 

	 	•	 	 Testing of environmental samples, including the detection of organisms, where the medical management of a human is not involved; 

	 	•	 	 Identity testing applications for forensic purposes or determination of paternity, excluding genotyping or other identification testing for medical management of a
human being or sample tracking in a clinical laboratory; 

	 	•	 	 In vitro diagnostic testing of non-human (plant or animal) samples, including animal breeding, pedigree determination, or gender determination;

	 	•	 	 Testing for the agricultural or food industries, including the identification of genetically modified organisms (GMOs) for these industries;

	 	•	 	 Sale or service of general purpose (“open”) instrument systems or general purpose reagents, including enzymes; unless such GPRs are specifically sold for
use with ASRs or other products regulated by the FDA or its foreign counterparts; 

	 	•	 	 Sale of non-exclusive information products and services not regulated by FDA (such as the Celera Discovery System) to any customers, including those customers
operating in the HIVD Field; 

	 	•	 	 Sale of anything labeled for therapeutic or prophylactic use; 

	 	•	 	 Sale of products or services that convey therapeutic or research patent rights; 

	 	•	 	 In- and out- licensing or other transfer of patents, technology or know-how for use in the therapeutic, research, or applied fields; 

	 	•	 	 Embryonic stem cell and recombinant cell characterization, testing, and quality control applications; and 

	 	•	 	 Epidemiology testing (the screening or testing of groups of people or populations for the study of the patterns, causes, or control of disease in groups of people)
and biosecurity testing (the detection of biological or chemical agents, pathogens, microorganisms or other infectious agents in the environment, agriculture, food or water), where the medical management of a human is not involved.

  

 2 

 Exhibit B 
 Specified Country List 
  

					
	Africa	  		  	
			
	 •   Algeria
	  	 •   Guinea
	  	 •   Senegal

	 •   Angola
	  	 •   Ivory Coast
	  	 •   Seychelles

	 •   Benin
	  	 •   Kenya
	  	 •   Sierra Leone

	 •   Botswana
	  	 •   Lesotho
	  	 •   Somalia

	 •   Burkina Faso
	  	 •   Liberia
	  	 •   South Africa

	 •   Burundi
	  	 •   Libya
	  	 •   Sudan

	 •   Cameroon
	  	 •   Madagascar
	  	 •   Swaziland

	 •   Cape Verde
	  	 •   Malawi
	  	 •   Tanzania

	 •   Central African Republic
	  	 •   Mali
	  	 •   Togo

	 •   Chad
	  	 •   Mauritania
	  	 •   Tunisia

	 •   Comoros
	  	 •   Mauritius
	  	 •   Uganda

	 •   Congo
	  	 •   Mayotte (France)
	  	 •   Western Sahara

	 •   Dem. Republic of Congo (Zaire)
	  	 •   Morocco
	  	 •   Zambia

	 •   Djibouti
	  	 •   Mozambique
	  	 •   Zanzibar

	 •   Egypt
	  	 •   Namibia
	  	 •   Zimbabwe

	 •   Equatorial Guinea
	  	 •   Niger
	  	
	 •   Eritrea
	  	 •   Nigeria
	  	
	 •   Ethiopia
	  	 •   Réunion
	  	
	 •   Gabon
	  	 •   Rwanda
	  	
	 •   Gambia
	  	 •   Saint Helena (UK)
	  	
	 •   Ghana
	  	 •   Sao Tome and Principe
	  	
			
	Asia	  		  	
			
	 •   Afghanistan
	  	 •   Hong Kong
	  	 •   North Korea

	 •   Bangladesh
	  	 •   India
	  	 •   Oman

	 •   Bhutan
	  	 •   Indonesia
	  	 •   Pakistan

	 •   Brit. Ind. Ocean Territory
	  	 •   Japan
	  	 •   Philippines

	 •   Brunei
	  	 •   Laos
	  	 •   Singapore

	 •   Cambodia
	  	 •   Macau
	  	 •   South Korea

	 •   China
	  	 •   Malaysia
	  	 •   Sri Lanka

	 •   Christmas Island
	  	 •   Maldives
	  	 •   Taiwan

	 •   Cocos Islands
	  	 •   Mongolia
	  	 •   Thailand

	 •   Cyprus
	  	 •   Myanmar
	  	 •   Vietnam

	 •   East Timor
	  	 •   Nepal
	  	
			
	Middle East	  		  	
			
	 •   Bahrain
	  	 •   Kuwait
	  	 •   Turkey

	 •   Gaza Strip
	  	 •   Lebanon
	  	 •   United Arab Emirates

	 •   Iran
	  	 •   Qatar
	  	 •   West Bank

	 •   Iraq
	  	 •   Saudi Arabia
	  	 •   Yemen

	 •   Israel
	  	 •   Syria
	  	
	 •   Jordan
	  	 •   Tunisia
	  	

  

 1 

 South America 
  

	•	 	 Argentina 

	•	 	 Bolivia 

	•	 	 Brazil 

	•	 	 Chile 

	•	 	 Colombia 

	•	 	 Ecuador 

	•	 	 Falkland Islands (UK) 

	•	 	 French Guiana (France) 

	•	 	 Guyana 

	•	 	 Paraguay 

	•	 	 Peru 

	•	 	 Suriname 

	•	 	 Uruguay 

	•	 	 Venezuela 

  

 2 

 Exhibit C 
 Forensics and Applied Markets 
  

	 	•	 	 Basic or applied research within academic, government, biotech, or pharmaceutical institutions; 

	 	•	 	 Quality assurance and quality control, including testing to determine conformance with specifications, purity, and batch-to-batch consistency within pharmaceutical
institution’s Process Development, Manufacturing, or Quality Control departments; 

	 	•	 	 Testing of environmental samples, including the detection of organisms where the medical management of a human is not involved; 

	 	•	 	 Human identity testing applications for forensic purposes or determination of paternity; 

	 	•	 	 In vitro diagnostic testing of non-human (plant or animal) samples, including animal breeding, pathogen detection, pedigree determination, or gender
determination; 

	 	•	 	 Testing for the agriculture or food industries, including pathogen detection and the identification of genetically modified organisms (GMOs) for these industries;

	 	•	 	 Stem cell and recombinant cell characterization, testing, and quality control applications; and 

	 	•	 	 Epidemiology testing (the screening or testing of groups of people or populations for the study of patterns, causes, or control of disease in groups of people) and
biosecurity testing (the detection of biological or chemical agents, pathogens, microorganisms or other infectious agents in the environment, agriculture, food or water), where the management of a human is not involved. 

 

 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]